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ABSTRACT

Introduction: The Consolidated Standards for Reporting Trials (CONSORT)
checklist has been formulated to improve the reporting of
randomized controlled trials (RCTs). The purpose of this
investigation is to determine predictors of CONSORT checklist
compliance in the oncology literature over the past two decades.

Methods:

Eight-hundred and fifty parallel two-arm RCTs assessing
oncological interventions in adult breast, prostate, colorectal, and
lung cancer between 1992-2010 were identified by a systematic
search of the medical literature. Exclusion criteria included
investigations reporting interim/secondary/long-term
update analyses, pilot or phase 2 studies, and studies not
employing a parallel design. After full article review, 408 articles
were eligible for inclusion into the CONSORT audit database. RCT
descriptive variables including number of authors/study patients,
2009 journal impact factor/journal classification, type of cancer and
therapeutic intervention, publication year, primary study country,
and cooperative group involvement were captured for all trials.
CONSORT guideline compliance was assessed by two qualified
auditors in order to generate average and difference CONSORT
checklist scores.

Results:

Mean average CONSORT score was 16.6 (SD 3, max 25) and
median difference score was 2 (interquartile range 1-3). Kappa
agreement for each individual CONSORT checklist item ranged
from (0.02-0.92) with an overall two-way intraclass correlation
coefficient of 0.71 (95%CI 0.61-0.78) for comparison of overall
CONSORT score between raters.

Recent year of publication,

increasing author number, and higher impact factor were
associated with higher average CONSORT scores
(p<0.0001). Recent year of publication was the only factor
associated with a decrease in the CONSORT difference score.

Conclusions: In this large reported CONSORT compliance audit in the medical
literature, improvements in RCT reporting have been observed over
\
time in the cancer literature. Further work in the assessment of the
inter-observer reliability of individual CONSORT items is warranted
given the observed kappa agreement heterogeneity.

Keywords:

Randomized Controlled Trial, Reporting, Quality,
Breast, Colorectal, Prostate, Lung, Cancer.
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1.0

Introduction

The Canadian Cancer Society publishes general cancer statistics on an
annual basis. In the current 2011 release, the main focus of this publication was
on the four most common cancers which include breast, colorectal, lung, and
prostate cancer).1 In 2011, the Canadian Cancer Society estimated that 177,800
new cases of cancer and 75,000 deaths will occur in Canada. Approximately
84,800 women and 93,000 men will be diagnosed with cancer, and of these
numbers approximately 35,100 women and 39,900 men will die of cancer in
Canada. On average, 487 Canadians will be diagnosed with cancer, and 205
Canadians will die of cancer every day. The Society also stated that lung,
prostate, breast and colorectal cancer account for 50% of all cancer deaths, and
50% of new cancer cases, with lung cancer accounting for over a quarter (27%)
of all cancer deaths; breast cancer accounting for over a quarter (28%) of new
cancer cases in women; and prostate cancer accounting for over a quarter (27%)
of new cancer cases in men (Figures 1 and 2).

Research into the cause, prevention, and treatment of cancer is a^highly
complex enterprise as documented by the following:

1.

Cancer research includes numerous areas and generally involves
extensive collaboration among several disciplines such as Molecular and
Physical Cancer Research, Cancer Imaging, Basic Cancer Biology, Basic
Cancer Physics, and Clinical Cancer Research.

2.

The conduct of cancer research is expensive. Even a basic science
laboratory that is operated by a single scientist might require funding
between CAN $50,000 to $500,000 per year to cover equipment and
salaries. Cancer cells required for just one experiment cost between

2

CAN$300 to $500.1Clinical research can be the most expensive. For
example, a review that included 28 Randomized Controlled Trials (RCTs)
reported total expenses of approximately US$ 335 million with a mean of
about US$ 12 million per RCT.2

3.

Besides financial costs, cancer research heavily consumes other
resources such as time and human effort. It can take several years and
the involvement of many investigators and participants in several centers
to complete a single study. For example, over the past 40 years a single
clinical trial group, the NCIC Clinical Trials Group, has enrolled about
45000 patients on various cancer clinical trials.3

The Randomized Controlled Trial (RCT) is an indispensible tool in to
investigate and assess various cancer treatments. Metaphorically, RCTs are the
bridge to transfer basic science knowledge to clinical practice. They are
frequently used to investigate a broad range of therapies as listed by the
Canadian Cancer Society:3
v
“1.

new anti-cancer drugs, including chemotherapy, hormonal therapy,
biological therapy and immunotherapy agents

2.

new approaches to cancer prevention, screening, surgery and radiation
therapy

3.

new combinations of treatments

4.

new ways of using standard treatments

5.

complementary and alternative cancer therapies

6.

supportive care to reduce the impact of cancer on emotions and
behaviour”

3

RCTs are used to validate new drugs and surgical procedures that are
potentially more effective than existing standard of care treatments for specific
types of cancer. Many of the cancer treatments that are used today were tested
and developed in clinical trials. Even the most promising scientific findings must
first be proven to be safe and effective in clinical trials before they can be
routinely utilized in clinical practice and be made available to the public.

The reporting of successfully completed RCTs is the final stage of clinical
research and is extremely important in the translation of acquired knowledge to
potential users of such information. A RCT literature report summarizes the trial
rationale, objectives, methodology, results, discussion and conclusion. Therefore,
hypotheses generated from preclinical and early clinical studies are tested in
more definitive RCTs, and then the knowledge gained from the findings are
transferred to clinical practice ideally through, in part, clear reporting in the
medical literature. Furthermore, studies have shown that RCTs with poor
reporting quality are associated with biased findings.4,5 Awareness concerning
the quality of RCTs reporting is growing. Inadequately conducted trials are
viewed as a waste of time, effort, and resources. Similarly, well-conducted trials
with inadequate reporting quality can represent a waste of these same
resources.

Various guidelines have been previously created to alleviate problems
arising from inadequate RCTs reporting.6 These various guidelines are currently
encapsulated by the “CONSORT - Consolidated Standards of Reporting Trials”
clinical trial reporting guideline that have been developed by the CONSORT
Group. The main product of CONSORT is the CONSORT Statement, first
published in 1996 with subsequent revisions in 2001 and 2010. The statement is
“an evidence-based, minimum set of recommendations for reporting RCTs. It
offers a standard way for authors to prepare reports of trial findings, facilitating

4

their complete and transparent reporting, and aiding their critical appraisal and
interpretation.’’6 A considerable number of journals worldwide and many editorial
bodies have approved and recommended the CONSORT Statement including
the International Committee of Medical Journal Editors, the World Association of
Medical Editors, and the Council of Science Editors.

Although there have been numerous recommendations over the past 30
years to enhance RCTs reporting, and more intensely over the past 15 years for
many medical literature publishers to attempt to adhere to the CONSORT
Statement; reviews in several fields of medicine have repeatedly shown that the
reporting quality is still problematic with poor adherence to the statement.7,8 To
our knowledge, an assessment of the quality of RCTs reporting and adherence to
the CONSORT statement in cancer research has not been previously attempted
or documented. Given the reliance on RCTs on progress in the fight against
various cancers over the last two decades as well as the proliferation of RCTs in
cancer research (and medicine in general), an audit of RCT reporting quality was
felt to be warranted by the study investigators.

The primary objective of this investigation is to determine predictors of
\

CONSORT checklist compliance in the oncology literature over the past two
decades. Some of the potential predictors to be assessed are Journal Name,
Type of Cancer, Publication Year, Number of Authors, Number of Patients,
Intervention, Trial Site, One VS Multiple Countries, Primary Country, Cooperative
Group, Impact Factor, Oncology VS Non-oncology Journal.

In addition, we plan for this investigation to shed light on the reliability of
the CONSORT checklist items in the cancer RCT context. It is hypothesized that
some of these items have clear working definitions, while others do not. This
investigation will examine whether the quality of reports of randomized trials has
improved over the past 20 years. We hypothesized that the quality of RCT

5

reporting has improved over the past 20 years given the increased utilization and
knowledge regarding RCT reporting quality statements such as CONSORT.

S
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Figure 1: Percentage Distribution of Estimated New Cases and Deaths for
Selected Cancers, Males, Canada, 2011
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Figure 2: Percentage Distribution of Estimated New Cases and Deaths for
Selected Cancers, Females, Canada, 2011

facentagt
N ot«:

Now casw exciude an astimawd 33,300 c a w « olnon-m «tenom a skin carvcw (basal and s<5uamoiB).
Death* tor *At Other Cancer** Include about 100 death* with undartytng causa *oth#f mattgnani
neoplasm»* ol alun,
AiwtyaJa by: Chronk: Disease Sorvaaanoe and Monaorin9 Division, CCOPC.PubficHeaithAaancy of Canada
Data aourcea: Canadian Cancer Reg>*try and Canadian Vital SiaiisticiDaaih databases at Statauc* Canada

Canadian Canoar Society: Canadian Cancer Slatlatfc* 3011

8

2. Randomized Controlled Trials (RCTs)

2.1

Historical Perspective

Around the year 600 B.C. Daniel of Judah conducted what might be the
first controlled clinical trial. This trial was a comparison of the health effects of a
vegetarian diet (vegetable and water) with those of a royal diet (meat and wine)
over a period ofte n days. At the end of the trial, the first group looked healthier
and seemed better nourished than the second group. By current research
standards this trial might have many drawbacks such as selection bias,
confounding, measurement bias, and others, yet it still stands as one of the
earliest clinical trials assessing different interventions for an important endpoint
(in the opinion of the observer).9

The 19th century witnessed chief developments in clinical trials. For
example, in the year 1836 the French trial studying the effect of blood-letting in
management of pneumonia by P. C. A. Louis10 had a very important influence on
medical science. This importance was captured clearly in a statement^published
in the American Journal of Medical Sciences "one of the most important medical
works of the present century, marking the start of a new era of science ... the first
formal exposition of the results of the only true method of investigation in regard
to the therapeutic value of remedial agents."

The 20th century witnessed the development of RCTs in a manner
consistent with modern RCT practices. A trial entitled “Streptomycin treatment of
pulmonary tuberculosis” published in 1948 was considered the first modern
RCT.11 Sir Austin Bradford Hill, one of this study’s authors, was given credit for
this achievement.9 However, in 2007, Forsetlund investigated when random

9

allocation was first used. His investigation revealed that RCTs had been used in
social and educational studies as early as 1928.12 In the second half of the 20th
century, RCTs were rightly regarded as a landmark principle that guided a new
era of rational evidence-based medicine. The methodology of the RCT has been
increasingly acknowledged, and its use has become almost universal to provide
a high level when it comes to quality of evidence. RCTs are considered the “gold
standard” for evidence-based medicine.13 As of 2004, more than 150,000 RCTs
have been cataloged in the Cochrane Library.9

2.2 Classifications of RCTs

The following are four common methods for classifying RCTs.
Classification by phase (Phase 1, 2 , 3 , and 4 trials), by type of design, by type of
hypothesis (superiority vs. noninferiority), and by clinical trial aim (explanatory v.
pragmatic) are routinely utilized in the literature and in practice.

The first method of classifying RCTs is by phase (Phase 1, 2, 3, and 4
trials).9These four phases are used to describe the different potential^
sequential steps in the process of investigating a new intervention, usually a new
drug. In general, this system of clinical trials is used to increase the efficiency of
data collection by testing interventions with increasing numbers of patients.
Additionally, the clinical trials move from safety endpoints in the early stages to
clinically relevant endpoints in later phases of clinical trial therapeutic intervention
development. It is important to note that not all phases are necessarily used for
all new therapeutic interventions.

As a first step after preclinical testing, a phase 1 trial is used to investigate
an intervention once the intervention is deemed safe in pre-clinical (animal)
research. Its purpose is to assess the safety of the intervention in humans, and
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to establish the therapeutic dose and maximum tolerated dose. Participants are
usually a small number of healthy volunteers, or patients who have failed all
conventional treatment and have no other standard options. Then, a phase 2 trial
is conducted once the intervention passes phase 1. Typically, the intervention is
given to a small group of patients that may benefit from treatment. Its purpose is
to establish the efficacy of different modes and doses of the interventions,
although data on safety is still collected and examined in order to establish the
therapeutic ratio of the intervention. Phase 1 and 2 trials are often combined into
one trial for efficiency of data collection. Once the safety and efficacy of the
intervention has been documented in a phase 2 trial, a definitive phase 3 trial is
conducted. Its purpose is to establish the effectiveness of the proposed
intervention(s) against a control group (placebo or current standard of care).
Participants are real patients generally numbering in the hundreds or thousands
based on an a-priori sample size calculation based on effect size, power,
variance, and alpha (usually 0.05). As a final optional step, phase 4 trial is
usually conducted after the marketing of the intervention. Its purpose is to
discover possible rare or late-occurring side effects not observed in phase 3 RCT
due to the limited follow-up and number of participants.
s
The second method of classifying RCTs is by the type of design. In a
comparative study of 616 RCTs indexed in PubMed in 2006, Hopewell et al
found that over three quarters (78%) of these reports were of parallel group trials,
16% were crossover trials, and the remaining 6% were cluster, factorial, or splitbody trials.14

In parallel group trials, individual participants are randomly allocated to one of
two (two-arm trial) or more intervention groups. All subjects in one group are
given the same a-priori defined intervention or placebo intervention if no standard
of care exists for the situation being studied. The group that receives the
investigated intervention is called the experimental group. The other group
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receives a standard of care intervention or no intervention and is routinely called
the control group.15 This is the most common trial design (over three quarters of
RCTs)14 as it is a straightforward design and its analysis is usually more
straightforward than the other designs.

In a cross-over trial, the participants in one group receive an initial
intervention then will be exposure to the other groups at a pre-determined point.
Thus, each participant in the trial will receive both interventions one after the
other but the order of exposure will be randomly assigned.15 A crossover design
has two potential advantages over non-crossover designs. First, the effect of
potential confounding is decreased because each participant serves as his or her
own control. Second, fewer participants are generally required in this type of
study.

In cluster trials predefined groups or populations of people rather than
independent participants, are randomly allocated to intervention groups. For
example: schools, towns, and cities can randomly be assigned to be given or not
given a specific intervention. Cluster randomized controlled trials have two main
advantages over individually-randomized controlled trials. First, this design
allows for the ability to control for the contamination effect among participants
(e.g., change in one participant’s behaviours may influence another participant’s
behaviours). Second, the ability to study interventions that cannot be directed
toward selected individuals (e.g. the use of a radio show directed to change
lifestyle targeted towards a population).16

In split-body trials, detached parts of an individual participant rather than
independent participants are randomly allocated to intervention groups. For
example: separate lesions on the skin, or the left and right eyes are randomly
given or not give an intervention.15 This design reduces in-between subjects
variation and bias. One of the disadvantages of this clinical trial design is the
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potential lack of independence among body parts in the same individual, which
creates special methodological challenges in the design, conduct, and analysis of
such trials. This disadvantage is a fundamental issue frequently discussed in the
published literature of Otology and Ophthalmology.17

In factorial trials, participants are allocated to groups of separate
interventions, combined interventions, and no intervention. For instance, a 2x2
factorial trial randomly allocates participants to four groups using two steps as
shown in Figure (3). In the first step they are randomly assigned to one of two
groups. One group is given intervention X and the other group is given placebo X
(Sometimes it is a different intervention not necessary placebo). In the second
step participants in each group are again randomly assigned to one of two
groups. One group is given intervention Y and the other group is given placebo
Y.

The effect of intervention X can be obtained from comparing groups 1 & 3

vs. 2 & 4, while the effect of intervention Y can be obtained from comparing
groups 2 & 3 vs. 1 & 4. The effect of intervention X and Y can be compared
against each other, combination of X and Y, and placebo.15 A factorial design
provides efficiency in answering multiple therapeutic questions as well as the
assessment of therapeutic interactions (additive and synergistic effects)
compared to a non-factorial one (e.g., it enables studying two interventions in
one sample instead of having to conduct two separate trials).

13

Figure 3: Trial w ith 2 x 2 Factorial Design
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The third method of classifying RCTs is by the type of hypothesis being
assessed in the trial (e.g. superiority vs. noninferiority).

In a superiority trial, the

null hypothesis is that the interventions have equal effects and the alternative
hypothesis is that they have different effects. Superiority trials constitute most of
published RCTs in the medical literature.18,19,20 In a noninferiority trial, the
hypothesis is that the first intervention has equal effect to the second
intervention, and the alternative hypothesis is that the first intervention is less
effective to the second one. Usually it is used to demonstrate that a new drug is
“as good as” an existing drug that is considered the standard of care, and usually
the new drug is more preferred for reasons such as lower cost or fewer adverse
side-effects. There are two requirements for noninferiority trials. First, a
noninferiority trial usually requires a much greater sample size than a trial whose
aim is to demonstrate a clinically significant difference to a control group.
Second, the definition of “clinical equivalence” between the two interventions
must be specified in advance as readers can and should be suspicious of studies
that apply 1-sided analyses without previous planning and reporting.19,20

The fourth method of classifying RCTs is by the fundamental trial aim and
v
approach. RCTs can be classified as explanatory (efficacy) or pragmatic
(effectiveness) clinical trials.9,21 Explanatory (efficacy) trials are conducted in ideal
setting, and designed to answer the question “Can the intervention work?”. In
these studies, the inclusion/exclusion criteria are very strict; poorly compliant
participants and those with conditions which might dilute the effect are often
excluded, the intervention is strictly enforced and adherence is monitored closely,
and the outcomes are often short-term surrogates or measures of effect.21
Pragmatic (effectiveness) trials are conducted in real life setting, and designed to
answer the question “Does the intervention work when used in normal practice?”.
In these studies, inclusion criteria are generally less strict and resemble the
target patient population of interest. The intervention may be applied flexibly as it
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would be in real world practice. Reported outcomes are directly relevant to
participants, funders, communities and healthcare providers.21

2.3

Randomization

Randomization is defined by Donner as a process where “participants
allocated to one of the groups (study, control) by a random mechanism which
assures that each of the participants has an equal chance of being assigned to
any group.”22 Randomization consists of two temporal steps. The first step is the
randomization procedure, in which investigators (or their delegates) generate a
random sequence to assign participants to trial groups. The second step is
allocation concealment, which is a set of strict preventative measures taken by
the investigators (or delegates) to make certain that the assignment sequence is
kept unknown and unpredictable until each participant has been officially
allocated to an intervention.

Proper randomization in RCTs facilitates blinding of the identity of
interventions from participants, investigators, and assessors. It allows the use of
probability theory (the likelihood that any difference in outcome between
treatment groups merely indicates chance.) and it enables comparability between
trial groups on factors (whether known or unknown) that may influence
outcomes.23,24

2.3.1 Randomization Procedures:

Randomization procedures can be classified as simple (unrestricted),
restricted, or adaptive.

Unrestricted Randomization
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This is also referred to as simple randomization or complete
randomization, and is the most common type of randomization seen in the
literature. Examples of this type of randomization are repeated coin-tossing and
computer based randomization. The main disadvantage of unrestricted
randomization is the possibility of generating unequal trial groups (by chance) if
the trial sample size is small. Therefore it is usually recommended in trials with a
sample size above 200 participants.25

Restricted randomization

Restricted randomization is also known as block randomization. The main
benefit of using this type of randomization is to generate equal trial groups
usually in the conduct of smaller tria ls .25The number of participants in one group
versus the number of participants in the other group(s) is pre-specified according
to a ratio that is called “allocation ratio”. To maintain the allocation ratio during
recruiting, participants are randomized within blocks according to the allocation
ratio.24 For example, if the allocation ratio were specified as 1:3, a bloqk size of 8
would force a random assignment of 2 participants to the first group and 6
participants to the second group. Block size can be fixed or variable so long as
participants in each block are randomized according to the same allocation ratio.
Varying the block size can reduce the predictability of the sequence.26

Adaptive Randomizations

This type of randomization is less commonly used compared to the previous
two types. This type can be classified into two main sub-types:
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1.

Minimization, also known as covariate-adaptive randomization: the
probability of being assigned to a group decreases or increases to
minimize potential imbalance between predictive factors (known factors).25
The first participant’s assignment is performed randomly, but the rest of
the assignment is adaptive based on previous assignments. Although this
procedure is quite robust in minimizing bias on known factors, the lack of
true randomization renders it less than optimal in minimizing bias on
unknown factors.27 Therefore, its adequacy as a robust randomization
procedure is considered controversial by many investigators.24

2.

Outcome-adaptive randomization: The chance of assigning a participant to
a group is directly related to the percentage of previous patients with
favorable outcome in that group. For example, if 80% of the subjects in
group A and only 50% of the subjects in group B have favourable
responses, the next recruited subject will be assigned to group A as it has
higher chances of favourable response at this point of the trial. This type of
randomization is usually used when investigating a serious disease like
AIDS where favourable patient outcomes are crucial.25
\

2.3.2

Allocation Concealment

Allocation concealment is defined as "the procedure for protecting the
randomization process so that the treatment to be allocated is not known before
the patient is entered into the study".28 The integrity of effective randomization
rests on appropriate allocation concealment. Although allocation concealment is
sought-after in RCTs,29 it is not always logistically followed in real-life practice.
Clinical investigators are not always neutral when it comes to their own patients
care. There have been incidences where clinical researchers have held up
sealed envelopes to lights to find out the allocation sequence in order to control
their next patient’s assignment.24 Such action voids the key benefits of

randomization, namely minimizing selection bias and confounding.24 Fortunately,
this breach could be largely prevented by various measures to prevent tampering
and in the varying of the block size if stratified randomization is utilized.

Intervention-group assignment can be performed at a central study office
by trained staff whose main responsibility is to preserve randomization validity. It
also can be performed by other means such as sequentially numbered sealed
opaque envelopes or sequentially numbered pre-randomized medication
containers.24 Due to the central role allocation concealment systems play in the
validity of an RCT, it is strongly recommended to report allocation concealment
systems in detail in the RCT protocol, as well as in the final published RCT
report. Unfortunately, most published RCTs have vague allocation concealment
in their protocols, in their reports, or in both.30

2.4

Blinding

Blinding (sometimes known as masking) in RCTs is a set of procedures
that ensures that individuals involved in the study do not know which étudy
participants are in which group (e.g. intervention vs. control).31 It is a
méthodologie approach that can be employed to decrease potential observation
bias and the ascertainment of outcomes bias. Furthermore, it preserves the
integrity of the randomization by preventing switching of participants from one
group to another by trial personnel.

RCTs can be classified into four types according to the level of blinding:32

1.

Open (Unblinded) RCT: All persons involved in the study are aware which
participant is receiving which intervention.33,34 If the intervention is a drug
treatment, the RCT is referred to as an open-label clinical trial.34
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2.

Single-blinded RCT: Either all participants or all investigators involved in
the study are unaware which participant is receiving which
intervention.36,37

3.

Double-blinded RCT: Both participants and investigators involved in the
study (usually patients and clinicians) are unaware which participant is
given which intervention.36,37

4.

Triple-blinded and quadruple-blinded RCTs: A triple-blinded RCT consists
of blinding of participants, investigators, and study evaluators and a
quadruple-blinded RCT consists of blinding of participants, investigators,
study evaluators, and statisticians.

In well-designed trials, other people such as patient caregivers and
proxies who do not play a role in treatment, measurement, or analysis might be
considered for blinding as well. The rationale for this kind of blinding stems from
the fact that caregivers’ actions potentially could influence treatment results, and
be influenced by knowing which treatment is given to the patient.38

In 2001 and 2006, two papers demonstrated that the terms "single-blind,"
"double-blind," or "triple-blind" have different meanings for different people.36,37
The 2010 Consolidated Standards of Reporting Trials (CONSORT) Statement

,

(which will be described in detail in chapter 3) recommended that authors should

!

be more transparent when reporting on blinding by specifying “who was blinded
after assignment to interventions (for example, participants, care providers, those
assessing outcomes) and how, If relevant, description of the similarity of
interventions”.27

Unlike allocation concealment, blinding is not always feasible, practical or
even possible. For example, most surgical studies are open-label because
blinding is usually impossible, impractical, and/or unethical with surgical
interventions. Another example, if the intervention requires the participant to
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perform an active role such as physical therapy. In this case, by definition,
blinding is impossible.31

2.5

Analysis of Data from RCTs

The characteristics of data and design dictate the type of analyses used in
RCTs. Analysis in RCTs could be simply classified as main analysis, subgroup
analysis, as well as missing data analysis.
1.

Main analysis: Statistical methods vary widely depending upon the type of
outcome data. To analyze binary (dichotomous) outcome data, logistic
regression and other methods can be used. To test the effects of predictor
variables for continuous outcome data, analysis of covariance can be
used. To examine time-to-event outcome data that may be censored (for
example, time to cancer death after receipt of chemotherapy in women
with breast cancer) survival analysis (e.g., Kaplan-Meier estimators and
Cox Proportional Hazards Models) can be used. Vittinghoff e ta l
presented, in table (1), different types of data, an example for each type,
and a proper method of analysis for it.

'
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Table 1: Type of outcome variable determines choice of multivariable regression model
(Vittinghoff eta!., 2005)39
Type of Data

Example

Regression Model

Continuous

Birth weight (grams)

Linear Regression (ANOVA)

Dichotomous

Low birth weight? (< 2500 grams)

Logistic Regression

Ordinal

Birth weight (Very low, low, normal)

Ordinal Logistic Regression

Nominal

Cause of death

Polytomous Logistic Regression

Counts

Incidence rate

Poisson Regression

Time to event

Time to death

Cox Model

\
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2.

Subgroup analysis: Analysis of subgroups could be utilized in some
RCTs.27 In the case of multiple statistical tests, the chance of finding at
least one test statistically significant due to multiple comparisons, and to
incorrectly declare a difference can quickly increase with the number of
such tests (a type I error). Multiple comparison correction methods such
as Bonferroni correction are used in this case to make the outcome
analysis more stringent and less likely to produce a type I error.

3.

Missing data analysis: Missing data in RCTs could be adjusted for by
many methods depending on the type of the data loss and its magnitude.
Options include analyzing only cases with known outcomes and using
imputed data.27

Regardless of the type of analysis, the following two considerations may
also apply with respect to clinical trial analysis:

1.

Interim Analyses: It is recommended that an RCT design include a pre
specified series of analyses as the data is being collected. TheVesult of
these analyses might suffice stopping the trial before the intended sample
size is reached. For instance, participants in one group experience a
"larger than expected benefit or harm," or if "investigators find evidence of
no important difference between experimental and control interventions."27

2.

Intent-to-Treat Analysis: In this type of analysis “data are analyzed in the
way patients were randomized, regardless of whether or not they received
the intended intervention.” 27 A "pure" intention-to-treat analysis is
"possible only when complete outcome data are available" for all
randomized subjects.33 For non-inferiority trials, intent-to-treat analyses
may not lead to the most conservative findings; therefore, per-protocol
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analyses where patients are analyzed depending on the actual treatment
received may be more appropriate.

2.6

Disadvantages of RCTs

Although RCTs provide the gold standard of evidence, they do have
disadvantages. Some of the most common explored shortcomings are listed
below:40

2.6.1

Limited Generalizability (External validity)

Generalizability is the applicability of study findings to real life practice.
Generalizability in RCTs could be restricted by many factors:40
1.

Quality of intervention: RCTs conducted in advanced research institutions
might use superior procedures compared to procedures used in real life
practice.

2.

Expertise of investigators: The expertise of the RCT medical te^m might
be different from the expertise of medical teams in real life practice.

3.

Setting and location: Findings of an RCT that was conducted on hospital
patients might not be applicable to patients seen in clinics.

4.

Participants’ Characteristics: Which can include age, sex, severity of the
medical condition, etc.

5.

Rare side effects: Side effects might be too rare to manifest in the sample
size of typical clinical trials.

2.6.2

Expenses
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Although RCTs are usually expensive,41 they have been shown repeatedly
to be cost effective from a societal point of view. For example, Johnston et a l 1
studied the cost and effect of 28 RCTs that were funded by the National Institute
of Neurological Disorders and Stroke. Their total expense was around US$ 335
million, and their return produced a net benefit to society at 10 years of 46 times
their total expense.

2.6.3

Pro-industry findings in industry-funded RCTs

The two main sources of most research funding are corporations
(including pharmaceutical companies) and government (including universities
and specialized government agencies). A small portion comes from charitable
foundations that usually deal with a specific disease such as Cancer, AIDS, and
Multiple Sclerosis.

Research has shown that results of RCTs supported by pharmaceutical
industry are more likely to be influenced compared to results of RCTs Supported
by other sources of funding. This influence systematically favors positive findings
for the products associated with the study sponsor.42 A systematic review of 30
RCTs conducted by Lexchin et al supported this conclusion (odds ratio 4.05,
95% C.L. 3, 5.5).43

It is difficult to pinpoint the exact percentage of published RCTs that did
not report funding, yet literature reviews have shown that a sizable portion of
them failed to do so. For example, a survey of 370 drug RCTs showed a 29%
failure to report rate.44 Another survey of 519 RCTs published in December 2000
in the medical literature showed a failure to report rate of 34%.45
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The influence of a funder on the result of an RCT might manifest in
several ways and to variable extent. It could be at the level of design, method,
analysis, and reporting. Consequently, it is crucial that the role of funders is
described in sufficient detail in the published report. Similarly, if the funder plays
no role in the conduct or reporting of a trial, a clear statement describing this
should be made in the report.46

2.6.4

Conditions for Use of RCTs

Another disadvantage in conjunction with RCTs is the requirement of
specific conditions for use of RCTs. To explain, the study exposure must be
changeable for a RCT to be utilized to gain knowledge. Factors such as genetic
traits, blood type, and family history are not modifiable, thus observation studies
are more appropriate design methodology in this situation. Although some
exposures such as smoking and marital status are changeable in principle, it is
impractical to alter them by the investigators for the purpose of research. For
example, all the available evidence on the negative health effects of smoking
was obtained through observational studies.
\

There should be true lack of certainty concerning which intervention
strategy is more beneficial. If there is existing evidence that drug A is superior to
drug B, it would be unethical to give a group of people the drug B. Additionally,
the primary endpoint is relatively common and prompt. The power of an RCT to
detect a statistically significant effect is directly dependent on the number of
endpoint events. Both rare and tardy endpoints require large sample sizes, which
is usually impractical and/or not feasible. Therefore, RCTs are not the preferred
tools when investigating interventions with rare or delayed outcomes.40

2.6.5

Statistical Error
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Statistical analysis in RCTs is subject to two types of potential error:

Type I Error (Alpha Error): The error of rejecting a null hypothesis when it
is actually true.47 In other words, it occurs when an RCT falsely concludes
difference between two interventions when a difference truly does not exist.

Type II Error (Beta Error): The error of failing to reject a null hypothesis
when in fact it is false. In other words, it occurs when an RCT falsely concludes
equality between two interventions when a difference truly does exist.

On the subject of Type II Error, a 1978 study stated that many published
RCTs, which failed to reject their null hypotheses, did not actually have a large
enough sample size to definitively support its conclusions. After three decades,
this unfortunate situation can still be observed in the literature. Several studies
documented in their review that a significant percentage of published RCTs still
had erroneous or less than optimal sample size calculations, which are the basis
for study power.48' 49

2.7

v

The Ethics of RCTs

Examining RCT from the ethical point of the view will be incomplete
without understanding the principle of clinical equipoise which is defined by
Freedman et al as “genuine uncertainty within the expert medical community...
about the preferred treatm ent",14 and referred to by Stolberg as “state of
knowledge in which no evidence exists that shows that any intervention in the
trial is better than another and that any intervention is better than those in the
trial."9

This concept basically stems from the fine balance existing between
possessing adequate proof that a new intervention is beneficial for a specific
condition and hoping that a clear-cut proof of this benefit will be proved. If there is
a proof that participants in one group in an RCT are more likely to benefit than
participants in the other group, the design of this RCT is unethical. It is only
ethical if RCTs are designed in areas of uncertainty, and should be conducted so
long as the uncertainty exists.

Special considerations might arise from the potential conflict between
clinical equipoise and benefit as perceived by patients, the public, and healthcare
professionals.18 For in-depth information on ethical concerns unique to RCTs
Heilm an50 provide an excellent discussion on the subject.

Even though an informed consent (permission given by a competent
patient based on understanding of all relevant facts) is almost universal in RCTs,
studies have showed that many participants are under the impression that the
treatment they received is favourable for their specific condition.51 Additionally,
the incorporation of RCTs in clinical research brought to existence cultural
considerations that yet to be examined and understood.52
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3.0

Reporting of RCT / Guidelines

3.1

Importance of RCT Reporting

It is important to differentiate between examining the quality of an RCT
and the quality of its reporting. The quality of RCT as defined by Moher et al is
“the confidence that the trial design, conduct, and analysis has minimized or
avoided biases in its treatment comparisons.” This main focus of this definition is
the quality of the methodology. On the other hand, Moher’s definition of the
quality of an RCT reporting, which is our primary interest here, was “providing
information about the design, conduct, and analysis of the trial.”53 It is important
to keep in mind that combinations of a poorly designed RCT that is well reported
or a well designed RCT that is poorly reported can occur in the medical literature.

Awareness concerning the quality of reporting randomized controlled trials
is growing. Inadequately conducted trials are viewed as a waste of time, effort,
and funds by funders and knowledge users alike. Similarly, well-cônducted trials
with inadequate reporting quality can represent a waste of the same resources
due to impaired knowledge translation. Interestingly, poor reporting quality is
paradoxically associated with an increased estimate of benefit for the
intervention.5

A chief obstacle hindering the assessment of RCT quality is that the
quality of reporting is often used as a proxy measure for méthodologie quality.
While research readers in most cases must rely on the information presented in
the written report to judge a trial and make inferences, essential méthodologie
details may be omitted from these written reports. Low-quality reporting may
hide important deficiencies in méthodologie quality, and it may hide strength in
well-conducted trials.54 Devereaux et al stated "health care providers depend
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upon authors and editors to report essential methodological factors in
randomized controlled trials (RCTs) to allow determination of trial validity (i.e.,
likelihood that the trials' results are unbiased)."55

Studies have proven that there is an association between poor reporting
and poor methodology in RCTs.54 Schulz et al investigated this association; his
conclusion was that “this study provides empirical evidence that inadequate
methodological approaches in controlled trials, particularly those representing
poor allocation concealment, are associated with bias. Readers of trial reports
should be wary of these pitfalls, and investigators must improve their design,
execution, and reporting of trials.”4 For example, trials that reported no exclusions
are more likely to have impaired concealed allocation.56

Some studies have considered the poor quality of statistical analyses as
the main reason for low quality reporting.57,58 “Trials should have a clearer
predefined policy for data analysis and reporting. The overuse of arbitrary
significance levels (for example, p < 0.05) is detrimental to good scientific
reporting, and more emphasis should be given to the magnitude of treatment
differences and to estimation methods such as confidence intervals.” 58

The importance of reporting is paramount due to the sizable amount of
taxpayer money, private funding, and charity fundraising invested year after year
in cancer research. The average cost of journal subscription paid by a university
library is $20,000 per year.59 Scientific publishing has become a multi billion
industry. For example, Elsevier Journals made £1 billion in pre-tax profit in
2003.60 Beyond these significant financial considerations, the well documented
incidents of research fraud play an equal and certainly more alarming reason to
examine and improve reporting quality.61 The “ publish or perish” culture
prevalent in academic medicine, together with the lack of consultation with
statisticians, has been attributed to what has been dubbed “the scandal of poor
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medical research”.57 The highest possible standards should be sought in the
performance and reporting of medical research, especially in regards to RCTs.

The ability to evaluate the méthodologie quality of RCTs is central to the
appraisal of individual trials, the conduct of unbiased systematic reviews, and the
performance of evidence-based health care. Whatever the outcome of a trial is,
poor reporting might lead to misinterpretation of the trial’s findings by the average
reader, health care providers in this case. Based on such misinterpretation
unfavourable changes to the clinical practice might occur, negatively affecting
patients’ care. It was said best by Devereaux et al “Until these inadequacies are
resolved health-care providers will remain limited in their ability to make informed
inferences about the validity of the studies upon which they base their clinical
practice.”55

3.2 RCT Reporting Guidelines / CONSORT

The broad goals of any reporting guidance are to improve the
transparency and reporting of the specific clinical trial design. The CONSORT
statement, which stands for CONsolidated Standards of Reporting Trials
statement, is broadly considered the current standard in RCT reporting as
evidenced by its adoption by important medical journal editorial groups. The
CONSORT group described the statement as “an evidence-based, minimum set
of recommendations for reporting RCTs. It offers a standard way for authors to
prepare reports of trial findings, facilitating their complete and transparent
reporting, and aiding their critical appraisal and interpretation.”62

The statement encompasses various initiatives developed by the
CONSORT group to alleviate the problems arising from inadequate reporting of

randomized controlled trials (RCTs). It is viewed as a part of the broader effort to
improve the quality of research used in decision-making in healthcare.

3.2.1 CONSORT Statement

The CONSORT Statement consists of a 25-item checklist and a flow
diagram along with some brief explanatory text. The statement also produced an
elaboration document with more detailed descriptions and examples. “The
CONSORT statement is intended to improve the reporting of a randomized
controlled trial (RCT), enabling readers to understand a trial's design, conduct,
analysis, and interpretation, and to assess the validity of its results. It
emphasizes that this can only be achieved through complete transparency from
authors.”6'63,64,65,66'67'68

The CONSORT Statement was designed to improve reporting of the
'standard' two-group parallel RCT design, but was not designed to address
reporting of the other types of RCTs, such as factorial and cluster RCT design.
To help improve the reporting of these alternative trial designs, extensions and
modifications of the statement have been underway by the CONSORT group,
who collectively considers the statement to be an evolving and improving
document. Therefore, it is subject to periodic changes as new evidence emerges.
The most up-to-date revision of the CONSORT Statement is the 2010 revision,
which can be freely viewed and downloaded from the CONSORT website
(http://www.consort-statement.org). There are current efforts to develop and
update extensions of the CONSORT Statement to address reporting quality for
other types of RCT designs.

32

3.2.1.1 CONSORT Checklist

The checklist consists of 25 items that focus on the reporting of how the
trial was designed, analyzed, and interpreted. Its main components are divided
into “Title”, “Abstract”, “Introduction”, “Methods", “Results”, “Discussion”, and
“Other Information”. These items were included in the checklist because
“empirical evidence indicates that not reporting the information is associated with
biased estimates of treatment effect, or because the information is essential to
judge the reliability or relevance of the findings."6,63’64,65,66

A copy of the checklist is below (Figure 4). In depth Details of these items
can be found in the CONSORT 2010 Explanation and Elaboration document.27,69

3.2.1.2 CONSORT Flow Diagram

The flow diagram (Figure 5) is intended to illustrate the passage of
participants through the four phases of a parallel RCT of two groups. These four
stages are enrollment, intervention allocation, follow-up, and analysis.^3,71 The
diagram explicitly shows the number of participants, for each intervention group,
included in the primary data analysis. The main function of the diagram is to
provide enough transparency to the reader to judge whether the investigators
have performed an intention-to-treat analysis.

3.2.2 CONSORT Explanation and Elaboration Document

The CONSORT group has endorsed a strong recommendation that
CONSORT Statement be used in conjunction with the CONSORT Explanation
and Elaboration Document. “This document is intended to enhance the use,
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understanding and dissemination of the CONSORT Statement. Through
examples and explanations, the meaning and rationale for each checklist item
are presented.”2769

3.2.3 CONSORT Endorsers

By the end of 2010, CONSORT had been endorsed by 435 medical
journals. To put this into context, it has been approved and promoted by over
50% of the core medical journals listed in the Abridged Index Medicus on
PubMed.72

CONSORT has also been endorsed by Medical Research Support
Foundation (MedicReS), and many editorial groups such as Council of Science
Editors, International Committee of Medical Journal Editors (ICMJE), and World
Association of Medical Editors (WAME). An up-to-date list of these journals and
organizations that have endorsed this statement can be found on the CONSORT
website (http://www.consort-statement.org).

s
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F ig u re 4 : C O N S O R T 2 0 1 0 c h e c k lis t (Ite m s h ig h lig h te d y e llo w a re th e o p tio n a l ite m s
t h a t w e re n o t c o n s id e re d in o u r s tu d y s c o re )

S e c tio n /
T o p ic

Ite m N o C h e c k lis t ite m

R e p o rte d o n
page No

T itle a n d a b s tra c t
1a

Identification as a random ised trial In the title

1b

Structured sum m ary o f trial design, methods, results, and conclusions (for
specific guidance see C O N S O R T for abstracts)

In tro d u c tio n
Background
and
objectives

2a

S cientific background and explanation o f rationale

2b

S pecific objectives or hypotheses

M e th o d s
Trial design

3a
3b

Participants
Interventions
Outcomes

Sample size

Description o f trial design (such as parallel, factorial) including allocation
ratio
Im portant changes to m ethods after trial com m encem ent (such as eligibility
criteria), with reasons

4a

Eligibility criteria fo r participants

4b

Settings and locations w h ere the data were collected

6b

The interventions fo r each group with sufficient details to allow replication,
including how and w hen they were actually adm inistered
Com pletely defined pre-specified prim ary and secondary outcom e
m easures, including how and when they w ere assessed
Any changes to trial outcom es after the trial com m enced, w ith reasons

7a

How sam ple size w a s determ ined

7b

W hen applicable, explanation o f any interim analyses and stopping
guidelines

8a

M ethod used to generate the random allocation sequence

8b

Type o f random isation; details o f any restriction (such as blocking and block
size)
M echanism used to im plem ent the random allocation sequence (such as
sequentially num bered containers), describing any steps taken to conceal
the sequence until interventions were assigned

5
6a

Randomisation:
Sequence
generation
Allocation
concealm ent
mechanism

9

Im plem entation

10

Blinding

W ho generated the random allocation sequence, w ho enrolled participants,
and w ho assigned participants to interventions

11a

If done, w ho w as blinded a fte r assignm ent to interventions (for example,
participants, care providers, those assessing outcom es) and how

11b

If relevant, description o f the sim ilarity o f interventions
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Statistical
methods

12a
12b

Statistical m ethods used to com pare groups fo r prim ary and secondary
outcom es
M ethods fo r additional analyses, such as subgroup analyses and adjusted
analyses

R e s u lts
Participant flow
(a diagram is
strongly
recom mended)

13a

For each group, the num bers o f participants w ho were random ly assigned,
received intended treatm ent, and were analysed for the prim ary outcom e

13b

Recruitm ent

14a

For each group, losses and exclusions after random isation, together with
reasons
Dates defining the periods o f recruitm ent and follow -up

14b

W hy the trial ended o r w a s stopped

Baseline data

15

Numbers
analysed

16

Outcomes and
estimation

A table showing baseline dem ographic and clinical characteristics for each
group
For each group, num ber o f participants (denom inator) included in each
analysis and w h eth er the analysis was by original assigned groups

17a

For each prim ary and secondary outcome, results for each group, and the
estim ated effe ct size and its precision (such as 95% confidence interval)

17b

For binary outcom es, presentation o f both absolute and relative effect sizes
is recom m ended
Results o f any o th e r analyses performed, including subgroup analyses and
adjusted analyses, distinguishing pre-specified from exploratory

Ancillary
analyses

18

Harms

19

All im portant harm s o r unintended effects in each group (for specific
guidance see C O N S O R T fo r harms)

Limitations

20

G eneralizability

21

Trial lim itations, addressing sources o f potential bias, im precision, and, if
relevant, m ultiplicity o f analyses
G eneralizability (external validity, applicability) o f the trial findings

Interpretation

22

Interpretation consistent w ith results, balancing benefits and harms', and
considering other relevant evidence

Registration

23

Registration num ber and nam e o f trial registry

Protocol

24

W here the full trial protocol can be accessed, if available

Funding

25

Sources o f funding and o th e r support (such as supply o f drugs), role o f
funders

D is c u s s io n

O th e r in fo r m a tio n

*We strongly recom m end reading this statem ent in conjunction with the C O N S O R T 2010 Explanation and
Elaboration fo r im portant clarifications on all the items. If relevant, we also recom m end reading CO NSO RT
extensions for clu ster random ised trials, non-inferiority and equivalence trials, non-pharm acological treatments,
herbal interventions, and pragm atic trials. A dditional extensions are forthcom ing: for those and for up to date
references relevant to this checklist, see w w w .consort-statem ent.org.

C O N S O R T 2 0 1 0 c h e c k lis t o f in fo r m a tio n t o in c lu d e w h e n r e p o r tin g a ra n d o m is e d tria l*
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Figure 5: CONSORT 2010 F low Diagram
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4.0

Measuring the Quality of RCT Reporting

4.1

Methods of Measuring the Quality of RCT Reporting

With an established rationale for the need to measure the RCT reporting
quality, we reviewed the literature to find a robust instrument or method that can
precisely make such measurement. The main three methods of examining the
quality of RCT reporting are: individual ratings, scales, and checklists.73

4.1.1 Individual Rating

Although raters usually attempt to exercise objectivity in their assessment,
their opinion depends completely on the knowledge and expertise of the rater. It
cannot be replicated and it changes over time. It is not likely to be the optimal
method to compare trials from different fields or different times.

4.1.2 Scales

\

A scale is an instrument that was designed to assign unit value to the
reporting quality. It consists of a number of items and each item has a digit score
with a predefined maximum and minimum score. The total score of these items
reflects the quality of the trial reporting. Scales theoretically are superior to
individual rating and checklists because they offer a quantitative value of the
reporting quality.

Scales differ from one another in the number of items, how items were
arrived at, what they measure, how reliable these items are in measuring what
they were intended to measure, approximate time to complete scoring a trial, the
range of the score, and how much weight each item is given. Using a specific
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scale to measure reporting quality might introduce certain biases. For example, a
scale that is constructed to give higher weight to blinding by definition penalizes
surgical RCTs in which blinding might be impractical or unethical.53

Between 1981 and 1993 twenty-five scales were developed to assess
RCTs.53 Of these only three were designed to assess reporting quality. W e have
listed these three scales with some of their characteristics in Table (2). The
Jadad scale is the only one that was validated using established méthodologie
procedures.73 Although the Jadad scale was validated, its low number of items
(n=3) renders it of limited value in evaluating the many facets of the complex
RCT design.

4.1.3

Checklists

A checklist is an instrument that was initially designed in a stepwise method
to guide authors in producing good quality reporting. Checklists could also be
used to assess reporting quality as well. Checklists differ from one another in the
number of items, how items were arrived at, what they measure, how reliable
these items are in measuring what they were intended to measure, anto how
much weight each item is given.

Between 1961 and 1993 ten checklists were developed to assess RCTs. Of
these, only three were designed to assess reporting quality.53 All three addressed
reporting of blinding, patient assignment and statistical analysis. None of the
three took into account reporting of follow-up. We have listed these three
checklists with some of their description parameters in Table (3).

All of the scales and checklists examined above have major weaknesses,
shortcomings that were to be addressed by the development o f the CONSORT
statement and checklist. In summary, these weaknesses include poor
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instructions on how to score, giving greater weight for some items, containing too
many or too few items, and being specific to a certain design of RCTs or to a
certain specialty.53

4.2 Using the CONSORT Checklist to Measure the Quality of RCT
Reporting

To examine the use of the CONSORT Checklist as measurement of the
quality of RCT reporting, we reviewed the literature for factors that should be
considered to help us make this judgment. We found a credible list of such
factors summarized in one of the most important works in the field of RCT
reporting by Moher e ta l. 53 W e measured the CONSORT Checklist according to
these factors and summarize the assessment in the following four points:

1.

Comprehensiveness of items: As demonstrated in Chapter 3 of this
document, the CONSORT Checklist is very comprehensive. Furthermore,
the checklist comprehensiveness could be established by two facts. First,
it includes all items that could be found in all the checklists and scales
presented earlier in this chapter. Second, it consists of 37 items, while the
number of items in the presented checklists and scales ranged from 3 to
34.53

2.

Ease of instructions: The checklist instructions were designed to be short,
to the point, and straightforward.

3.

Definition of the study population: The checklist was originally designed to
improve reporting quality of the “standard' two-group parallel RCT design
and was developed and adopted by many core medical journals.

4.

Number of citations (studies that used the checklist as a scale): we can
see in the coming chapter, almost all audits of reporting quality after the
publication of the CONSORT Statement 1996 have used the CONOSRT
checklist as a scale, whether in whole or in part. By the end of the year
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2010 the number of such studies as reported in the CONSORT website
was 95.74
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Table 2: Description of three scales constructed to measure the quality of randomized
controlled trials reporting
N a m e of
G e n e ric
S cale’s
vs.
Author with
specific
P ubM ed ID #

A n d re w 78

S

Q uality
defined

No

# o f Inter-rater
A v erag e
# of
citation
item s a g re e m e n t * tim e to
* * *
com plete
(m in utes) **

11

.95

10

clear
instructions
on how to
score

Reporting
Blinding

Reporting
type of
statistical
analysis

Reporting
type of
assignm ent

Reporting
follow up

Y es

Y es

Yes

Y es

No

N /A
Annals:™

G

Yes

34

.12

15

193

Y es

Y es

Yes

Y es

No

J a d a d :'3

G

Yes

3

.6 6 - .77

< 10

122

Y es

Y es

Yes

Y es

No

* In te r-ra te r a g r e e m e n t a s re p o rte d b y a u th o r s
** A v e r a g e tim e to c o m p le te s c o r in g o n e s tu d y a s re p o rte d b y a u th o rs , o r a s e s tim a te d by :63
*** N u m b e r o f a r tic le s th a t c ite d th e s c a le in P u b M e d

\
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Table 3: Description of three checklists constructed to measure the quality of randomized
controlled trials reporting
N a m e of
Checklist's
Author with
P ubM ed I D #

G e n e ric Q uality
vs
defined
specific

# of
In ter-rater
item s a g re e m e n t *

A v e ra g e
tim e to
com plete
(m inutes)

# of
citation

Reporting
Blinding

Reporting
typ e of
assignm ent

Reporting
type of
statistical
analysis

Reporting
follow up

*«#

clear
instructions
on how to
score

*■ *

D e rS im o nia n : 71

N /A

No

11

15

263

N /A

Yes

Y es

Y es

Y es

G rant :78

N /A

No

28

20

N /A

N /A

Yes

Y es

Y es

Y es

Mahon : 'a

N /A

No

4

10

101

N /A

Yes

Y es

Y es

No

* In te r-ra te r a g r e e m e n t a s re p o rte d b y a u th o r s
** A v e r a g e tim e to c o m p le te s c o r in g o n e s tu d y a s re p o rte d b y a u th o rs , o r a s e s tim a te d b y :63
*** N u m b e r o f a r tic le s th a t c ite d th e s c a le in P u b M e d

\
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5.0

Previous Works in RCT Reporting Quality in the Literature

5.1

RCT Reporting in Several Medical Fields

Alm ost all studies investigating the reporting quality of RCTs have
concluded that improvements in RCT reporting have been observed after the
introduction of the CONSORT Statement, yet the overall quality of the trials
remains unsatisfactory.80 The following paragraphs summarize some of the
important studies in this field.

In the Pediatric literature, Al-Namankany et al published a study in 2009
that assessed published RCTs in Paediatric dental journals between 1985 and
2006. The inclusion criteria as stated by the author were “(i) the trial was a
randomized clinical trial; (ii) the trial was published between 1985 and 2006, and
in English; (iii) the trial participants were infants and children, aged 18 years or
under; and (iv) the article had been published in one of the paediatric dental
journals specified." The two main aims were to determine “(i) whether quality of
reporting allows readers to assess the validity of trials; and (ii) whethe) quality of
reporting has improved since the introduction of the CONSORT guidelines”. The
report included 173 articles. The authors concluded that “the quality of reporting
of clinical trials is poor, and often not adequate to allow readers to assess trial
validity. Overall quality of reporting has not substantially improved since the
publication of CONSORT”. The authors sent letters to the journals included in the
study, to ascertain their status regarding the adoption of the CONSORT
guidelines. Only two of the five journals responded to the letter, stating that they
have not yet adopted CONSORT statement.81

In Cardiology literature, Ethgen et al published a study in 2009 evaluating
the quality of published reports of RCTs assessing stents for percutaneous
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coronary interventions. Their sample size was 132 RCTs, and their conclusion
was in line with the previous study in that the current reporting needs to be
improved to allow readers to judge the risk of bias and the applicability of the
results. One possible explanation provided by the authors for the poor quality
was in reporting primary outcomes “in about half of the reports, the main
outcomes relied on angiographic evaluation such as coronary restenosis or late
lumen loss. These outcomes are surrogates of clinical events, ... and may prove
challenging for the interpretation of results,”82

In a plastic surgery study published in 2008, Taghinia et al analyzed RCTs
with respect to reporting standards, méthodologie quality, and impact on the
specialty as RCTs in plastic surgery have not been analyzed comprehensively
before that date. Their analysis included 163 RCTs published from 1986 to 2006
in three major plastic surgery journals. They used the CONSORT checklist to
score these RCTs. Their conclusion read, “there were deficiencies in the
reporting of parameters that influence bias and statistical significance. The
reporting and méthodologie standards of randomized controlled trials in plastic
surgery need improvement”. The main areas with poor reporting quality identified
by the study were statistical analysis, sample size determination, blinding,
randomization, sequence generation, and allocation concealment.83

In the Dermatology literature, Adetugbo et al published a survey study in
2000 in which they examined the reporting quality of all published parallel group
RCTs in Clinical and Experimental Dermatology from its inception in 1976
through 1997. As measures of reporting quality the authors examined the
adequacy of randomization, trial sample size, baseline comparisons, and
intention-to-treat analysis. A total of 68 RCTs were included in their analysis. Of
these trials, only 1% reported the method of random sequence generation, 1%
reported sample size and statistical power considerations and had an a priori
main hypothesis, 7% reported adequate concealment of allocation. Among 38
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trials that used simple randomization, the sample sizes in the comparison groups
were identical in 22 occasions; raising the possibility that simple randomization
might not have been adequately generated or concealed. Their final statement
read “there is the need for higher methodological quality in clinical trial reporting
in dermatology journals. The adoption of the CONSORT (Consolidated
Standards of Reporting Trials) statement and checklist for the reporting of trials
should enhance the validity of and strengthen the evidence from clinical trials
reports”.84

In the Urology literature we found a study published in 2007 by Scales et
al. Their sample included 152 published RCTs from 1996 to 2004, and their
assessment of reporting quality was based on the CONSORT checklist. The
authors had two main conclusions: “reporting in the urology literature has
improved since the publication of the Consolidated Standards of Reporting Trials
statement in 1996...certain areas, such as reporting of trial methods, continue to
meet Consolidated Standards of Reporting Trials criteria in fewer than half of
publications”. The areas with poor reporting quality identified by the study
included: calculation to justify sample size, randomization method specified,
allocation concealment, who generated allocation sequence, who enrolled
participants, who assigned participants to groups, participants blinded,
Intervention personnel blinded, assessors blinded, flow diagram, and intent to
treat analysis.85

In Occupational Therapy, a study by Moberg-Mogren et al investigated the
quality of reporting in published RCTs by using a modified CONSORT checklist.
The kappa statistics computed on individual items ranged from .58 indicating
high levels of agreement for most items to .40 indicating low levels of agreement
for some of the items. The study concluded that a few of the CONSORT items
are impossible to comply with in most occupational therapy research, such item
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11 “Blinding”. However, most of the items are possible to report as recommended
by CONSORT.86

A systematic review by Plint et al analyzed the results of 8 studies that
were conducted to determine whether the adoption of the CONSORT checklist is
associated with improvement in the quality of reporting of randomized controlled
trials (RCTs). Their unit of analysis was published reviews on CONSORT
adherence. Their search was able to identify 8 eligible studies published between
1996 and 2005. Their results proved an association between journal adoption of
CONSORT Statement and improved reporting of RCTs.87

Pat et al published a study in 2008 that examined adherence to the
CONSORT statement in RCTs with information on symptom control and quality
of life during chemotherapy for advanced non-small cell lung cancer. The
CONSORT Checklist was used as a scale for adherence to the statement (a
proxy for reporting quality). On the contrary to the findings in the previous studies
(above), the overall adherence of RCTs to CONSORT in this study was found to
be acceptable with no clear sign of change over time.88
\

Although most of the studies above have shown improvements in RCT
reporting quality after the introduction of the CONSORT Statement with
unsatisfactory overall quality, others have shown contradicting findings. This
uncertainty in the literature warrants further research.

5.2

RCT Reporting in Cancer Research

Very few studies have investigated the reporting quality of RCTs
published in Oncology journals.49 Our literature search was only able to identify
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six studies, none of which directly examined RCTs reporting in breast, prostate
colorectal, or lung cancer. Following is a brief description of these studies.

One of them is the study mentioned above published by Pat et al in 2008.
Another example is a study published in 2008 by Mathoulin-Pelissier et al. This
study limited its evaluation to reporting of survival endpoints in 104 phase III
trials. Their initial electronic search and review of abstracts identified 274 cancer
RCTs while their full article review revealed that only 104 of these articles were
indeed RCTs. Their main conclusion was stated as “A majority of articles failed to
provide a complete reporting of survival endpoints, thus adding another source of
uncontrolled variability”.89

Ziogas et al published an article in 2009 in which they evaluated the
reporting quality of published RCTs concerning myeloid hematologic
malignancies. Quality of reporting was assessed using a 24-item questionnaire
based on the CONSORT checklist. Their search identified 261 eligible RCTs.
Their findings were summarized, as “Quality of reporting in RCTs focusing on
myeloid malignancies remains unsatisfactory. Further improvement of reporting
\

is necessary to assess the validity of clinical research”.

Kober et al published a study in 2006 that examined reporting quality as
assessed by adherence to the CONSORT statement in published RCTs with
information on patients with Hodgkin lymphoma. The sample size was 242 RCTs
and the quality of reporting was assessed using a 14-item questionnaire based
on the CONSORT checklist. Reporting was evaluated in two pre-CONSORT
periods (1966-1988 and 1989-1995) and one post-CONSORT period (19962002). Their main conclusion was “Despite recent improvements, reporting levels
of CONSORT items in RCTs involving patients with Hodgkin lymphoma remain
unsatisfactory”.91
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In 2009, Bekelman et al published a study in which they hypothesized that
radiotherapy RT reporting may be inadequate in Hodgkin's lymphoma (HL) and
non-Hodgkin's lymphoma (NHL) phase III RCTs. They searched PubMed and the
Cochrane registry for relevant RCTs published between 1998 and 2007. Their
initial abstract review identified 133 RCTs while their full article review revealed
that only 61 of these articles were indeed RCTs. Their assessment depended on
the presence of six quality measures: target volume, radiation dose, fractionation,
radiation prescription, quality assurance (QA) process use, and adherence to
QA. Their main conclusion was stated as “Reporting of RT in HL and NHL RCTs
is deficient.”49

Bentzen et al published a study in 1998 to assess the quality of the
design, analysis, and reporting in RCTs with information on radiation oncology.
The authors were motivated by special concerns in relation to the reporting of
radiotherapy RCTs. One of their conclusions was “we need to improve the quality
of RCTs in terms of their design, conduct, analysis and reporting.”48
\

Although the reporting quality of RCTs has been investigated adequately
in RCTs published in different fields of medicine, such an investigation seems to
be lacking in RCTs published in oncology journals, which in the opinion of our
research team warrants further research.

5.3 Predictors of Reporting Quality

Although several studies have evaluated the quality of RCTs published in
medical journals, our review revealed that very few studies tried to determine the
predictors of CONSORT checklist compliance.
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The first example is a study that was conducted by Lai et al and published
in 2006. It found that impact factor, publication after 1995, and sample size more
than 280 were significant factors associated with better overall reporting quality.
It also concluded that the reporting quality of RCTs in the primary treatment of
brain tumors is suboptimal.80 The second example is a study that was conducted
by Barbui et a lto assess whether the impact factor is a proxy measure of the
reporting quality. The sample included 132 RCTs and the results revealed that
the impact factor is not a valid measure of reporting quality.92

Our review revealed that studies identifying predictors of CONSORT
checklist compliance are very few. This may be due, in part, to the relatively
recent adoption of the checklist, which did not allow enough time for thorough
understanding of the predictors and the relationships among them. The
importance of determining predictors of CONSORT checklist compliance stems
from the fact that identifying and overcoming the obstacles of improving RCT
reporting quality may help health-care practitioners and research consumers to
make informed inferences about the validity of the studies upon which they base
\

their decisions.

5.4

Reliability of Individual CONSORT Items

Again, although several studies have evaluated the quality of RCTs
published in medical journals, few studies tried to investigate the reliability of the
CONSORT Checklist items (the following are two examples of such studies), and
none were conducted with a focus on cancer research.

In 2007, Farrokhyar et al published a study examining the quality of
reports of RCTs in coronary artery bypass grafting (CABG) surgery when
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comparing off- and on-pump techniques. Their data came from electronic
searches of MEDLINE, the Cochrane Library, CINAHL, HealthSTAR and
EMBASE, and they used the CONSORT Checklist to score the quality. Two
interesting points were mentioned in this publication: “The kappa value was
greater than 0.6 for 73 of 105 (70%) items”, and “the quality of the publications'
reporting methods, results and discussion sections was suboptimal”.93 Another
study by Moberg-Mogren et al demonstrated similar findings. The kappa statistics
computed on individual items of the CONSORT checklist ranged from 0.58 to
1.00 indicating high levels of agreement for most items. However, some item
kappas fell below the moderate level of agreement 0.40.86 This demonstrates
that there might be real weakness in the working definitions of the checklist
items. If such results are confirmed, improving the reporting quality of RCTs may
be performed by identifying the unclear items and improving their reliability in
future versions of the CONSORT checklist.

The reliability of the CONSORT checklist items is crucial for improving the
reporting quality of RCTs. It enhances the use, understanding, and dissemination
of the CONSORT statement. Because of this importance, the CONSORT group
has a strong recommendation that the statement be used in conjunction with the
CONSORT Explanation and Elaboration Documents. These documents present
the meaning and rationale for each checklist item.27,69

As we stated above, very few studies tried to investigate the reliability of
the CONSORT Checklist items, and none of them did that in RCTs published in
Oncology journals. Further research inquiry in this area is warranted.
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5.5

Clinical Articles Inaccurately Presented as RCTs

It was interesting to find that the literature contains many clinical articles
that were inaccurately presented as RCTs. For example, Mills et al conducted a
study to examine the CONSORT compliance in clinical pharmacology journals.
Two points were reported. First, of the 482 clinical trials included in the initial
search, only 193 were considered to be RCTs after study review. Second, the
use of the certain CONSORT items was questionable in these journals, possibly
because many items may not be relevant to clinical pharmacology research.94
Another example is one of the cancer studies mentioned above.89 The initial
electronic search and review of abstracts in this study identified 274 cancer
RCTs while their full article review revealed that only 104 of these articles were
indeed RCTs.

5.6

Summary of the Literature Review

The main points of our review can be summarized in the fact that to date
there has been no study that assessed the reporting quality of published RCTs
involving common cancers. Research on determining predictors of CONSORT
checklist compliance and on examining the reliability of the CONSORT Checklist
items is lacking in the literature and especially in the oncology literature. Also,
scientific data are lacking with regards the reliability of the CONSORT checklist
items.

Based on the limited reliable information on the reporting quality of
published RCTs in oncology and on the importance of cancer as a disease entity
associated with significant morbidity and mortality, we decided to study the
predictors of CONSORT checklist compliance in the oncology literature. We also
decided to examine the reliability of the CONSORT Checklist items, and to
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examine whether the reporting quality of RCTs in the oncology literature has
improved over the past two decades.
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6.0 Objectives and Hypotheses

6.1

Study Objectives

1.

To determine predictors of CONSORT checklist compliance in the
oncology literature over the past two decades.

2.

To examine the reliability of the CONSORT checklist items.

3.

To examine whether the quality of reports of randomized trials has
improved over the past 20 years.

As we demonstrated in the Chapter 5, these three questions have been
previously unanswered. Scientific data are lacking with regards to the first two
questions, and evidence is inconsistent concerning the third one.

6.2

Study Hypotheses
'x

Null Hypothesis: There is no association between CONSORT statement
compliance/accuracy and the following variables Journal Name, Type of
Cancer, Publication Year, Number of Authors, Number of Patients,
Intervention, Trial Site, One vs. Multiple Countries, Primary Country,
Cooperative Group, Impact Factor, Oncology vs. Non-oncology Journal.

Alternate Hypothesis: An association exists between CONSORT
statement compliance/accuracy and the following variables Journal Name,
Type of Cancer, Publication Year, Number of Authors, Number of
Patients, Intervention, Trial Site, One vs. Multiple Countries, Primary
Country, Cooperative Group, Impact Factor, Oncology vs. Non-oncology
Journal.

i
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7.0 . Methods

7.1

Study Design

The study design is a cross-sectional CONSORT compliance audit of
published parallel two-arm RCTs assessing oncological interventions in adult
breast, prostate, colorectal, and lung cancer between 1992-2010.

7.2

Setting and Relevant Dates

This study was conducted in collaboration between the Departments of
Oncology and Epidemiology & Biostatistics, University of Western Ontario,
London, Ontario, Canada. The selection of the study sample was conducted
between May and June 2010. Data collection was performed between June and
November 2010. Data analyses were performed between November 2010 and
January 2011.
' V

7.3

7.3.1

Study Population

Inclusion/Exclusion Criteria

In choosing our inclusion and exclusion criteria, we desired to select
RCTs that the majority of oncologists may be exposed to during their years of
practice.

These criteria are described in the following two subsections.

7.3.1.1

1.

Inclusion Criteria:

Published phase III RCTs from 1992 to 2010: To meet this criterion, a trial
must have been a prospective study that assessed healthcare
interventions in human participants who were randomly allocated to study
groups.

2.

English language

3.

Involving adults: A specific age range is not specified as many of the
RCTs included in the study did not report such ranges.

4.

Cancer type: Breast, Prostate, Colon, and Lung (four most common adult
solid tumors)

5.

Parallel group design: constitutes the majority of published RCTs

6.

Studies published in journals that published >4 RCT studies in the 20
years period: Practically, journals that publishes less than 5 RCTs on one
of the four cancer types in a period of about 20 years are not ideally
considered journals that routinely publish on oncology topics.

7.3.1.2

Exclusion Criteria

1. "

Non-English language reports

2.

Investigations reporting interim analysis that did not result in stopping the
trial

3.

Secondary and long-term update (primary report available) analyses

4.

Pilot/phase 2 studies
/

5.

Trial that did not employ a parallel design such as cross-over, factorial,
cluster, split-body and multiple arm trial. (For definitions please see
chapter 2)

6.

Duplicate reports

7.

. Cost effectiveness and economic studies

8.

Trials studying benign tumours or pre-cancerous lesions

9.

Trials studying cancers other than the four mentioned in the inclusion
criteria, or a combination of two or more of these four cancers.

7.3.2

Selection Methods

Selection of reports was performed in three stages:

7.3.2.1 Database Search (Stage 1)

A professional librarian at the London Regional Cancer Program
conducted a search of PubMed database for RCTs in compliance with the study
inclusion criteria. SEARCH STRATEGY: randomized controlled trials as
topic[mh] AND (quality control[mh] OR guideline adherence[mh] OR guidelines
as topic[mh] OR publishing/standardsfmh] OR publication/standards[mh]). Eighthundred and fifty parallel two-arm RCTs assessing oncological interventions in
adult breast, prostate, colorectal, and lung cancer between 1992-2010 were
identified.

; 7.3.2.2

,

Titles and Abstract Review (Stage 2)

One reviewer screened the titles arid abstracts of the 850 retrieved reports
to exclude any obvious reports of non-eligible trials. Of these, 515 RCTs were
deemed eligible for inclusion in a full article review.
v

7.3.2.3

'

’ ’’

Full Article Review (Stage 3)

A copy of the full article was obtained for each of the 515 Included reports
with any additional material about the article such as an appendix on the journal
that published the article. Two qualified reviewers conducted a full article review
of the 515 non-excluded reports. One of the two reviewers is a Canadian Medical
Graduate Involved In this work during his Oncology residency training and the
other is an International Medical Graduate (with Canadian medical qualifications)
involved in this work as a requirement to complete a Clinical Epidemiology
Master’s program. This review had three goals, first to exclude any reports of
non-eligible trials, second, to score the included reports using the CONSORT
checklist, and third, to collect data on specific variables for further analyses. Of
the 515 RCTs, 408 RCTs were deemed eligible for inclusion into the RCT
oncology database. Each one of these RCTs was given a number from 1 to 408
termed as ID Number in order to provide a straightforward unique clinical trial
identifier for data management.

7.4 Variables

7.4.1

Primary and Secondary Outcomes

'n

'

:

Primary Outcome Measure: The average of two “CONSORT Scores” (see
scoring procedure below) for each RCT is termed the CONSORT average score.
This average is considered a measure of quality as measured by two
independent reviewers.

Secondary Outcome Measure: The difference between these two scores
is termed the CONSORT difference of scores. This difference reflects
disagreement between the two raters, and is considered an estimate of reliability
- i.e. the higher the difference score, the less reliable the checklist is for that
specific clinical trial.
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7.4.2 Variables (Predictors)

1.

Journal Name: The name of the journal in which the trial was published.

2.

Type of Cancer: The type of cancer under investigation in the trial.
Categorized as a nominal variable.

3.

Publication Year: The year in which the trial was published. We
categorized this continuous variable into three groups: (1992-1996),
(1997-2001), and (2002-2010).

4.

Number of Authors: The number of authors of the trial. In the main effects
model, we used this variable as a continuous variable. In the descriptive
analysis, we categorized this continuous variable into groups of three
authors. W e considered groups of three authors as a reasonable and
meaningful number to present these data for histogram purposes. The
number of authors in our sample varied between 1 - 36 authors.
Categorizing the variable into groups of three authors reflects an increase

^

of about 10% that is traditionally considered the rule of thumb in
epidemiology if standard categories did not exist in the literature.

5.

Number of Patients: This is equivalent to the trial sample size. In the main
effects model, we used this variable as a continuous variable. In the
descriptive analysis, we categorized this continuous variable into groups of
250 patients. W e considered groups of 250 patients a reasonable and
meaningful number to present these data. The number of patients in our
sample varied between 30- 5187 patients. Categorizing the variable into
groups of 500 (according to the 10%) will cause most of the RCTs to fall in
one group as most of them in our study have a sample size of less than
500.

6.

Intervention: The intervention under investigation in the trial. Nominal
variable categorized into four groups: Radiation, Chemotherapy, Surgical,
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and Multiple Therapy (Any combination of Radiation, Chemotherapy, and
Surgical).
7.

Trial Site: The number of sites where the trial was conducted. Binary
variable, 0 if the trial was conducted in one site, and 1 in two sites or more.
For example, if a trial was conducted in four hospitals, the Trial Site value
is 1.

8.

One vs. Multiple Countries: The number of countries where the trial was
conducted. Binary variable, 0 if the trial was conducted in one country, and
1 in two countries or more.

9.

Primary Country: The name of the country where the trial was originated.
Nominal variable.

10.

Cooperative Group: W hether the trial was conducted by a cooperative
group or not. Binary variable (1 for cooperative group, and 0 for noncooperative group).

11.

Oncology vs. Non-oncology: W hether the trial was published in an
Oncology or Non-oncology journal. Binary variable (1 for Oncology, and 0
for Non-oncology).

12.

Impact Factor: The impact factor (IF) is a measure reflecting the average
number of citations to articles published in science and social science
jo u rn a ls .95W e dichotomized this ordinal variable into two groups: Low £
10, and High >10. After completion of data collection, we found that these
cut-off points can be written as Low ^ 7.667, and High £ 14.069 as our
sample did not include trials from journals with impact factors in between
7.667-14.069. The cut-off point of 10 was chosen because the literature

j

suggests that “good” journals are generally going to have an IF greater
than 10.96

r

7.4.3 Potential Confounders
\

,
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Both the association between CONSORT Average Scores and the
predictors, and the association between CONSORT Difference of Scores and the
predictors might be confounded by several variables. Here is a list of these
potential confounders:

1-

Journal Name: Potential confounder for both Impact Factor and Oncology
vs. Non-oncology.

2-

Trial Site: Potential confounder for both Number of Patients and Number
of Authors.

3-

Cooperative Group: Potential confounder for both Number of Patients and
Number of Authors.

4-

Type of Cancer: Potential confounder for intervention.

5-

One vs. Multiple Countries: Potential confounder for trial site.

These potential confounders were suspected through insight in the
relationship between the variables. To identify confounders we used the classical
criteria of confounding “A variable is a confounder if it is associated with
exposure and causally related to the outcome.” For example, the variable “one
vs. multiple countries” is suspected to be a potential confounder because it fulfills
the first condition (It is logically associated with exposure “trial site” as a trial
conducted in multiple countries, by definition, has more than one trial site), and
may fulfill the second one (may be causally related to the outcome “reporting
quality”). Disproving one of these two conditions is sufficient to rule out the
confounding effect. This could be done through the main effects model by
showing whether associations between variables (potential confounders) and the
outcome exist;

7.5

Data Sources and Measurement (Scoring)
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Compliance with the CONSORT checklist guidelines was assessed by two
qualified reviewers in order to generate average and difference CONSORT
checklist scores. W e used the CONSORT Checklist as an extraction form. We
included only 25 items of the checklist 35 items. The excluded items were the
items defined by the checklist as optional (highlighted yellow in checklist, and the
last three items in the checklist Other Information items Figure (4). Our rationale
for these two exclusions was as follows:

1.

Inclusion of optional items might penalize trials in which these items do not
apply. For example, inclusion of Blinding, an optional item, penalizes most
of the surgical trials in which Blinding is impossible or impractical.

2.

The last three items in the checklist were added to the 2010 revision of the
checklist. Inclusion of these items will not measure adherence to
CONSORT Guidelines published before 2010.

Each RCT was given a score out of 25, reflecting how many of the 25
extraction form items were complied with (with each item being given equal
weighting), this score was termed the “ CONSORT score” . Before data collection
started, and to ensure similar understanding of the scoring process by the two
reviewers, a sub-sample of 10 articles was randomly selected from the sample of
articles included in Stage 3. The two reviewers discussed the interpretation of
the different items. Differences primarily lend themselves to differing
interpretation of the data extraction form items. In the event of disagreement,
discussion took place with the senior investigator (Dr. George Rodrigues) until
concordance was reached.

7.6

Efforts to Address Potential Sources of Bias

To reduce potential measurement bias in:
1.

Stage 3: The optional items were excluded when constructing the
extraction form.

2.

Stage 3: The two reviewers independently scored the articles

3.

Analysis: The small number of predictors relative to the large sample size
(408 articles) ensures minimal biased estimates of the regression
coefficients.

To reduce potential inter-observer error in Stage 3:

1.

To reduce the number of data entry steps, data were directly entered into
the database (Excel Sheet).

2.

To ensure similar understanding of the scoring process by the two

^

reviewers, a subsample of 10 articles were randomly selected for

1

establishing definition, and to assess intra-observer agreement
respectively.

3.

Quality assurance on all steps of data collection, entry, and management
was performed. Twenty percent of the overall sample was randomly
selected and evaluated again by each one of the reviewers to double
check the scores for inter-observer error.
'n

To reduce potential selection bias:

\
v

1.

In Stage 2: Of the 850 articles included through Stage 1, the senior
investigator and a qualified reviewer initially screened 200 articles.
Discussion took place when screening each of these 200 articles to
ensure complete understanding of the inclusion and exclusion criteria.

2.

In Stage 3: T he choice of the ten-article subsample was random. A digit
between 0 and 9 was chosen randomly, and then articles with an ID
number ending with this digit were included in the sub-samples.
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7.7 . Study Sample Size

A traditional sample size calculation is not possible as there is no known
estimate of what clinical importance may be in the case of RCT reporting quality.
Therefore we considered estimating the sample size as a function of the number
of coefficients that can be safely included in the study analysis. The commonly
used rule of thumb is ten observations per variable, a ratio of 10:1.97

Since we intended to analyze the association between two outcome
measures and eleven predictors (13 variables or coefficients), according to the
above rule the minimum sample size is 130 RCTs. Any ratio greater than 10/1, a
sample size bigger than 130 RCTs, should generate regression coefficient
estimates that are precise. The greater the ratio, the more precise regression
coefficient estimates are likely to be. “The model which optimizes the biasvariance trade-off is by definition the model which minimizes prediction error."98

'n

7.8

Quantitative Variables

\

Publication Year: W e categorized this continuous variable into three
groups. The cut-off points were chosen to allow us to examine the
difference in reporting quality among three time periods: Pre-CONSORT
(1992-1996), between the release of CONSORT and its first revision
(1997-2001), and between the release of the first CONSORT revision and
its second revision (2002-2010).

Impact Factor: W e dichotomized this ordinal variable into two groups: Low
< 7.667, and High > 14.069.

7.9 . Statistical Methods

7.9.1

Statistical Analysis

W e calculated Kappa statistics for each individual CONSORT item and for
the total scores on the entire sample of 408 articles. Also, descriptive summary
statistics were calculated for all variables. The main analysis was performed by
constructing two main effects models. In the first main effects model we looked at
the association between the predictors (Intervention, Year of Publication, Trial
Site, Cooperative Group, Cooperative group, Oncology Journal type, Number of
Authors, Number of Patients, and Impact Factor) and the CONSORT Average
Score (predictors of quality). In the second, we looked at the association between
the above predictors and the CONSORT Difference of Scores. Backward
elimination analysis was used to identify all potential confounders. A p-value of
<0.05 is considered statistically significant. All statistical analyses were
conducted using SAS Software 9.2 (SAS Inc. North Carolina, USA).

7.9.2.

Ethics Approval

\

This study used previously published data making it exempt from
institutional review board approval.

8.0: Results

8.1

Participants
The PubMed search produced 850 potentially eligible publications. This

group was examined for eligibility by screening the titles and abstracts. A total of
335 studies were excluded and 515 publications were found eligible in this stage.
A fter a full article review of these 515 publications, a total of 107 studies were
excluded and 408 publications were confirmed eligible for inclusion in the final
analysis. Figure (6) presents a flowchart depicting the study screening process.

8.2

Descriptive Data

Results from the descriptive analyses carried out to assess demographic
characteristics of the 408 RCTs included in the study are shown in Figure (7).
'n

Frequency by year of publication shows that the number of RCTs published in
the three time periods (1992-1996), (1997-2001), and (2002-2010^ were 51, 84,
273 RCTs respectively. Frequency by trial site shows that most of the trials were
conducted in more than one site (377 RCTs), and much fewer were conducted in
one site (31 RCTs). Frequency by number of countries shows that 156 RCTs
were conducted in multiple countries and 252 RCTs were conducted in one
country. Frequency by type of intervention shows that 13 RCTs investigated
radiation therapy, 349 RCTs investigated chemotherapy, 1 RCT investigated
surgical therapy, and 45 RCTs investigated a combination of the previous three
therapies.

Frequency by type of cancer shows that 273 RCTs investigated lung
cancer, 135 RCTs investigated breast cancer, 41 RCT investigated prostate
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cancer, and 59 RCTs investigated a colorectal cancer. Frequency by journal
shows that Journal of Clinical Oncology published a significant proportion of our
sample (178 RCTs). Annals of Oncology published 52 RCTs. Each one of the
other journals published < 21 RCTs. Frequency by primary country shows that
107 RCTs originated In the United States. Each one of the other countries
published < 35 RCTs. Frequency by Oncology vs. Non-oncology shows that 374
RCTs were published In Oncology journals vs. 34 RCTs were published in non
oncology journals.

Figure (7) provides Information on the predictors under investigation
(Journal Name, Type of Cancer, Publication Year, Number of Authors, Number of
Patients, Intervention, Trial Site, One vs. Multiple Countries, Primary Country,
Cooperative Group, Oncology vs. Non-oncology, and Impact Factor). Category
boundaries for quantitative data, for Sample Size, Number of Authors, and
Impact Factor are displayed in Figure (7).

Our data did not find any significant confounding effect of the suspected
potential confounders. This study used previously published data; therefore,
there was no missing data for any of the variables of Interest.

8.3

Outcome Data

Four hundred and eight articles were approached for descriptive analysis.
Our primary outcome was the CONSORT Average Scores; the mean average
CONSORT score was 16.6 (SD 3, max 25). Our secondary outcome was
CONSORT Difference of Scores; the median difference score was 2 (Interquartile
range 1-3).

Four sets of descriptive statistics are presented in table (4) for all articles.
Three of them are descriptive analysis of (mean, median, range): 1. Descriptive

statistics for the CONSORT Scores by the first reviewer, 2. Descriptive statistics
for the CONSORT Scores by the second reviewer, 3. Descriptive statistics for the
CONSORT Average Scores. The fourth set is a descriptive analysis (including
interquartile range, median, interquartile deviation).

Figure (8) presents the distribution of the two outcome measures. The
CONSORT Average Scores show a bell-shape distribution, while the CONSORT
Difference of Scores shows a distribution that is skewed to the right. Four
hundred and eight articles were approached for calculation of the one-way, twoway random, and two-way intraclass correlation coefficients (ICC) between the
CONSORT Scores generated by the two reviewers. Good correlation was seen
between the two raters; the overall two-way intraclass correlation coefficient was
0.71 (95%CI 0.61-0.78) for comparison of overall CONSORT score between
raters. Figure (9) presents a scatter plot of this correlation. Table (5) presents the
one-way, two-way Random, and two-way missed intraclass correlation
coefficients (ICC).

Four hundred and eight RCTs (entire sample) were approached regarding
the reliability in the final analysis. Kappa agreement for each individual
CONSORT checklist item ranged from (0.02-0.92). Percent agreement for each
individual CONSORT checklist item ranged from (30.9 - 97.8%). Table (6)
presents simple Kappa statistic and percent agreement for each of the
CONSORT checklist items.
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F ig u re 6: F lo w c h a r t d e p ic tin g th e s tu d y s c r e e n in g p ro c e s s . T h e P u b M e d s e a rc h p ro d u c e d
8 5 0 p u b lic a tio n s . F ro m t h is g ro u p , 5 1 5 p u b lic a tio n s w e re e lig ib le a fte r s c r e e n in g th e title s
a n d a b s tra c ts . F ro m t h is g r o u p , 4 0 8 p u b lic a tio n s w e re e lig ib le f o r in c lu s io n in th e a n a ly s is
a fte r a f u ll a r tic le re v ie w .
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Figure 7: C h a ra cte ristics o f 408 RCTs and Inform ation on R eporting Q uality P redictors
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Table 5: Reliability Analysis Intra-rater correlation Coefficient (One-way, two-way Random, and
two way Mixed), Data from 408 RCTs.
Form

Model

ICC (95% C.l.)

ICC(1,1)

OneWay

0.70(0.65,0.75)

ICC(2,1)

Two Way Random (Raters Random)

0.71(0.61,0.78)

ICC(3,1)

Two Way Mixed (Raters Fixed)

0.74(0.69,0.78)

Table 6: Simple Kappa and Percent Agreement For Each of the CONSORT Checklist Items
Using Data from 408 RCTs.
C h e c k lis t Ite m

K a p p a S ta tis tic s

P e rc e n t A g re e m e n t

R a n d o m iz a tio n (1 a )

0.93

96.32

D e s ig n s u m m a r y (1 b )

0.88

96.57

B a c k g r o u n d (2 a )

0 .1 4 *

87.50

O b je c tiv e s (2 b )

0 .1 6 *

87.75

D e s ig n (3 a )

0.66 *

90.67

P a rtic ip a n ts E lig ib ilit y (4 a )

0.30 *

97.79

S e ttin g s a n d L o c a tio n s (4 b )

0 .5 5 *

87.25

In te r v e n tio n s (5)

0 .3 7 *

94.12

P rim a ry a n d S e c o n d a ry (6 a )

0.55 *

80.88

S a m p le S iz e (7 a )

0.56 *

85.30

S e q u e n c e G e n e ra tio n (8 a )

0.49 *

82.60

S e q u e n c e G e n e ra tio n (8 b )

0.59 *

84.32

A llo c a tio n m e c h a n is m (9 )

0.39 *

71.32 A

Im p le m e n ta tio n (10)

0 .1 0 **

76.71 A
\

B lin d in g (1 1 a )

0 .5 2 *

82.00

S ta tis tic a l M e th o d s (1 2 a )

0.56 *

96.80

F lo w f o r P a tie n ts (13a)

0.24 **

71.32 A

F |o w f o r L o s s to F o llo w u p (1 3 b )

0 .2 7 **

61.03 A

0.88

95.10

B a s e lin e d a ta (1 5 )

0.28 *

96.57

N u m b e r o f p a tie n ts A n (1 6 )

0.05 *

58.82 A

P rim a ry a n d S e c o n d a ry (1 7 a )

0.05 *

51.96 A

H a rm s (1 9 )

0.40 *

88.73

V

R e c r u itm e n t D a te s (1 4 a )

L im ita tio n s (2 0 )

0 .3 9 *

70.59 A

G e n e r a liz a b ility (2 1 )

0.04 **

30.89 A

In te r p r e ta tio n (2 2 )

0 .0 3 **

92.65

0.81

97.30

P r o to c o l (2 4 )

0 .1 8 **

94.37

F u n d in g (2 5 )

0.78 *

90.20

R e g is tr a tio n (2 3 )

K a p p a S ta tis tic a n d P e rc e n t A g re e m e n t f o r e a c h o f th e c h e c k lis t ite m s
* K a p p a S ta tis tic < 0 .8 0

R e d < 0 .3 0

** K a p p a S ta tis tic < 0 .3 0
A P e rc e n t A g re e m e n t < 8 0 % .
C o e ffic ie n t in te r p r e ta tio n (> .8 0 A lm o s t p e rfe c t, .61 - .80 S u b s ta n tia l, .41 - .60 M o d e ra te , .21 - .40 F a ir, 0 .20 S lig h t, < 0 P o o r) G u id e lin e s f o r in te r p r e ta tio n o f r e lia b ility . ( A fte r L a n d is a n d K o c h , 19 77 )
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8.4 . Main Results

The result of the main effect model analysis of the 408 articles was as
follows. Recent year of publication, increasing author number, and higher impact
factor were associated with higher CONSORT average score (p<0.0001). Recent
year of publication was the only factor associated with a decrease in the
CONSORT difference score. Two points support the precision of the model. First,
the normality of the distribution o f CONSORT Average Scores that is evident in
the bell-shape distribution shown in Figure (8). Second, the main effect model
contains more than 10 observations / variable “Models with fewer than 10
observations/variable, require greater assurance that random errors are normally
distributed, i.e. can then not rely on central limit theorem.”97

The main effects model disproved the second of the two conditions for
classical criteria of confounding “a variable is a confounder if it is associated with
exposure and causally related to the outcome”98 by showing that there was no
association between each of the potential confounders (Patient Number,
Oncology vs. Non-oncology, Cooperative Group, Intervention,'Cancer Type, and
Trial Site) and the outcome. Disproving this condition was sufficient to rule out
the confounding effect in our data.

8.4.1

CONSORT Average Score

Recent year of publication: Results from Table (7) demonstrate a dose
response relationship in which later publication year reflects an increase in
reporting quality. There was an average increase of 3.1 CONSORT score points
comparing an RCT published between 2002-2010 to an RCT published between
1992-1996, and an increase of 1.8 CONSORT score points comparing an RCT
published between 2002-2010 to an RCT published between 1997-2001.

. Author Number: higher author number was associated with a
higher CONSORT Average score (p<0.0001). There was an increase of 1 point
in the CONSORT Score in published RCTs for an increase of about 7 in the
num ber of authors, Table (7).

Impact Factor: higher impact factor was associated with a higher
CONSORT average score (p<0.0001). RCTs published in journals of a high
Impact Factor have higher CONSORT Average score (1.46 point higher)
compared to RCTs published in journals with low impact factor, Table (7)

8.4.2. CONSORT Difference Score

Recent year of publication: This predictor was the only factor associated
with a decrease in the CONSORT difference score (This difference reflects
disagreement between the two raters, and is considered an estimate of the
reliability of the checklist). For example, there was a decrease in CONSORT
difference score comparing an RCT published between 2002-2010 to an RCT
published between 1992-1996 (p=0.0085).

Table (7) presents the results of the main effect model of the association
between predictors on one hand and CONSORT average score (reporting
quality) and CONSORT score difference (predictors of variability) on the other
hand. Table (8) reports category boundaries when continuous variables
(Publication Year and Impact Factor) were categorized.

8.5

Other analyses:
Four hundred and eight articles were utilized for calculation of the

correlation between CONSORT average score and Impact Factor. A weak
Pearson’s correlation was seen 0.34. From looking at the entire plot of this
correlation Figure (10), we could observe a stronger correlation between these
two variables for articles with an impact factor of less than 32.
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Table 7: Factors Affecting CONSORT Average Score (Reporting Quality), and CONSORT Score
Difference (Predictors of Variability) using data from 408 RCTs.
Variable
s
Intervention*

Radiation vs. MultipleA
Chemo vs. MultipleA
Surgical vs. MultipleA

Year of
Publication**

(1992-1996) vs. (2002-2010)A
(1997-2001) vs. (2002-2010)A

Trial Site (Single vs. m ultiple^
Cooperative Group (Non-Cooperative vs.
Cooperative^
Journal Type (Non-oncology vs. OncologyA)
No. of Authors
No. of Patients
Impact Factor¥ (High vs. lowA)

CONSORT
Average
Estimate
1.54
0.63
1.21

p-value
0.0481
0.1139
0.6306

CONSORT
Difference
Estimate
-0.48
-0.28
1.91

-3.10
-1.82

<.0001
<.0001

0.70
0.07

0.0085

-0.71
-0.31

0.1510
0.2043

-0.07
-0.08

0.8405
0.6186

0.46

0.3406

0.02

0.9636

0.15
0.0001
1.46

<.0001

-0.03
-0.0002
-0.25

0.1899
0.1670
0.1661

0.6602

<.0001

p-value
0.3694
0.3020
0.2697

0J491

* T he variab le Intervention Is categorized into fo u r groups: Radiation, Chemo, Surgical, and Multiple Therapy
(Any com bination o f Radiation, Chemo, and Surgical).
x
** T he variab le Y e ar o f Publication is categorized into three groups: Pre-consort (1992-1996), between the
release o f C O N S O R T and its first revision (1997-2001), and between the release o f the first CO NSO RT revision
and its second revision (2002-2010).
A R eference group
¥ T h e variable Im pact Factor is an O rdinal variable that is dichotom ized into two groups: Low: £ 7.667, and
High: s 14.069. Low is the reference group. The re was no journal that has an im pact factor between these two
values

;
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Table 8: Category Boundaries of Publication Year and Impact Factor using data from 408
RCTs.
Publication Year
Category 1

(1992-1996)

Category 2

(1997-2001)

Category 3

(2002-2010)

Impact Factor
Category 1

Low: £ 7.667

Category 2

High:

14.069

V
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9.0

Discussion

9.1

Discussion

9.1.1

Predictors of CONSORT Checklist Compliance

Our primary aim was to determine predictors of CONSORT Checklist
compliance in the oncology literature over the past two decades and the
magnitude of their effects. W e identified three statistically significant predictors of
quality in the oncology literature including Year of Publication, Impact Factor, and
Author Number.

O f these three predictors the Year of Publication was the one with the
highest impact on the checklist compliance (i.e with the largest coefficient value).
There was an increase of 3.1 in the CONSORT Score comparing an RCT
published between 2002-2010 to an RCT published between 1992-1996, and an
increase of 1.8 in the CONSORT Score comparing an RCT published between
2002-2010 to an RCT published between 1997-2001.

V
This result might be explained by several factors that have changed over
the two decades. With the increase in the number of researchers trying to
publish, publishing became more competitive. Journal editors have raised the
publication standards and the editorial instructions have become clearer and
stricter. Also the process of peer review became more regulated. The number of
peer reviewers increased from one peer reviewer to three or more, and strict
rules were put in place to minimize potential biases in the process such as
blinding the peer reviewers to the names of authors and institutions.

Another factor that might have increased the quality of reporting is the
existence of cooperative group clinical trials. Cooperative groups require internal
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peer-review before sending the article for the external peer-review, which may
have significant down-stream effects of improved reporting.

Another possible factor is the advancement in technology. This
advancement has a clear impact on the way research is conducted. In recent
years many research tools became more available such as more robust
statistical software, clearer and easier to construct graphs and databases,
improvements in publishing and word-processing software, and faster internet
access.

Advancement in technology did not only affect the way research is
conducted, but also the way it is presented and published. The open access
movement enabled the publication of many RCTs that would not be published if
online access were not available. Although more access might be viewed as
leading to less competitiveness, traditional journals have been striving to
distinguish their publications by increasing their quality over time.

The predictor with the second largest coefficient was the journal impact
factor. RCTs published in journals of a high impact factor have a higher
CONSORT average score (1.46 point higher) compared to RCTs published in
journals of low impact factor.

It would have been counterintuitive if the impact factor was not associated
with better reporting quality. High impact factor journals are more competitive to
successfully publish medical research work. They usually require more strict
publication instructions and peer review process. Therefore, RCTs published in
these journals have better methodological quality compared to ones published in
low impact factor journals. This result is congruent with previous literature,80,82 in
that good methodological quality is associated with good reporting quality in
RCT. ■

' '

The predictor with the smallest coefficient was the total author number.
There was an increase of 1 point in the CONSORT Score in published RCTs for
an increase of about 7 in the number of authors. Intuitively, larger research
team s have the advantages of more feedback and internal reviews. Members
from different backgrounds bring to the equation different experiences and
perspectives, and thus potentially broaden a team’s base of knowledge. For
example, having a statistician on the team ensures a more through insight in the
statistical part of the reporting.

Although this association is statistically significant, it does not seem to
present practical importance. If we considered this finding to be equivalent to a
strong linear association, author numbers would go up substantially. For
example, if an RCT has 6 authors with a reporting quality of 16 points, and we
need to increase the quality of a report to 21 points (Maximum of 25 points),
keeping all other variables the same, the number of authors of an article should
be increased to 41 authors. This number is not financially feasible, nor sensibly
practical.

2

Reliability of the CONSORT Checklist Items

'

Kappa agreement for each individual CONSORT checklist item ranged
from (0.02-0.92). Percent agreement for each individual CONSORT checklist
item ranged from (30.9 -97.8%). Our data showed that a few of the checklist
items have poor Kappa values yet high levels of agreement. This counterintuitive
relationship was presented and explained by Feinstein in a paper titled “High
agreement but low kappa: The problems of two paradoxes”99 published in the
Journal of Clinical Epidemiology. “In a fourfold table showing binary agreement
of two observers, the observed proportion of agreement can be paradoxically
altered by the chance-corrected ratio that creates kappa as an index of
concordance. In one paradox, a high value of proportion of agreement can be
drastically lowered by a substantial imbalance in the table's marginal totals either

vertically or horizontally.” In other words, for rare finding, very low values of
kappa may not necessarily indicate low rates of overall agreement.

CONSORT checklist items [Allocation mechanism (Item # 9 ),
Implementation (Item # 1 0 ) Flow for Patients (Item # 13a) Flow for Loss to Follow
up (Ite m # 13b) Generallzabllity (Item # 21) Interpretation (Item # 22)] were the
least clear to interpret by the two reviewers Figure (4). These items were
identified based on a combination of the values of the Kappa statistic and the
percentage agreement for each item, and then on a discussion between the two
reviewers after data collection and analysis.

Previous works in the field have shown similar results. For example
Moberg-Mogren et al found that the kappa statistics computed on individual items
ranged from high levels of agreement for some items to ones that fell below the
moderate level of agreement.86,93

Recent year of publication was the only factor associated with an increase
in reliability of the CONSORT checklist items (decrease in the
CONSORT difference score which is considered an estimate of variability
p<0.0001). There was a decrease in CONSORT Score difference comparing an
RCT published between 2002-2010 to an RCT published between 1992-1996
(p<0.0001). This result could be explained by the same possible reasons
mentioned above to explain the increase of the reporting quality in recent studies.

The variability in the level of agreement for some items (a proxy for item
reliability) is likely multi-factorial. One possible explanation of the variability in the
levels of agreement for some items is that the fact that the CONSORT statement
was adopted by many journals does not mean that these journals literally use the
CONSORT checklist as their guidelines; rather they integrate the statement’s
recommendations in their own guidelines. For example, although the Journal of
General Internal Medicine (JGIM) adopted the CONSORT Statement, authors or

peer, reviewers interacting with the journal should use the JGIM Review Guideline
as a guideline. Variability in the integration of the statement’s recommendations
may result in lowering the reliability of some of the checklist items. A second
possible explanation is that some of the checklist items might be more applicable
for certain specialties or procedures. For example, allocation concealment might
be easier to explain and report in drug trials than in surgical trials. A third
possible explanation is that the wording of some of the checklist items and the
instructions on how to use them are indeed unclear. Also, a baseline level of
variation is expected with any interpretative activity including this audit of the
oncology literature.

In all cases, collaborative efforts to improve the wording of the checklist
items and the working definitions related to these items are sought. Such
collaboration would be more effective if all stakeholders were involved in the
process, whether be journal auditors, authors, peer reviewers, librarians, and
research consumers etc. Further incorporation of the CONSORT statement in
graduate and post-graduate studies may result in a more universal
understanding of its definitions. Finally, further research in this area may help in
improving the reliability of the CONSORT items too.

9.1.3

J

^

RCT Reporting Quality over the Past 20 Years

The results that have been noted by previous research describing RCT
reporting 86,89 has been confirmed herein. Although improvements in RCT
reporting have been observed over time in the cancer literature, the overall
quality of reporting remains suboptimal (Mean average CONSORT score was
16.6 [SD 3, max 25]). By looking at these numbers from a percentage point of the
view we can safely say that 50% of the published literature has a reporting
quality of 66.4% or less (16.6/25 x 100), and 85% (one standard deviation above

the mean) has a reporting quality of 78.4% or less (19.6/25 x 100) based on the
CONSORT statements consensus definition of reporting standards.

By looking at these percentages in the context of the CONSORT
statement, we can see that the reporting quality of published RCTs in oncology
RCT-based research is less than optimal. This may be the result of several
obstacles. Identifying and overcoming these obstacles may help health-care
practitioners and research consumers to make informed inferences about the
validity of the studies upon which they base their decisions. Further research in
this area is warranted.

In the 515 reports included in the full article review, 107 had unclear
abstracts. These abstracts included information about the study design that
presented the report as an RCT while the full article review revealed that the
report was not. Many research consumers depend only on the abstract to obtain
the research results and level of evidence. It is therefore alarming that a fifth
(107/515) of the literature might provide inaccurate information in this regard.
O ther studies found similar or less optimal results. For example, the initial
electronic search and abstract review in a similar study identified 274 cancer
V
RCTs, while their full article review revealed that only 104 of these articles were
indeed RCTs.89 In another example, the initial electronic search and abstract
«
review identified 482 clinical trials, while their full article review revealed that only
193 were indeed RCTs.94

Confounding: Unlike other studies, our study did not find any significant
confounding effects of the study potential confounders (as described in the
methods section) on the association between the study predictors and the
reporting quality.
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9.2. Generalizability

This study does have several factors affecting its generalizability. The
study sample was derived from a single database, PubMed, this increases the
reliability (internal validity) of the study results, yet reduces the generalizability
(external validity) of these results when applying the same question to RCTs
published in other databases. From searching the literature we found two studies
by Plint et al, and Farrokhyar et al with similar results to our study. Both studies
obtained their data from electronic searches of (MEDLINE, EMBASE, and
Cochrane CENTRAL) and of (MEDLINE, the Cochrane Library, CINAHL,
HealthSTAR and EMBASE) respectively, and both used the CONSORT checklist
to score the quality.87,93

Thé study investigated the four most common cancer types. These types are
responsible for around 60% of all cancer incidences and cancer caused death.
Since research studying the other cancers is conducted in almost similar pattern
(same countries, institutions, and journals), it might be possible, with caution, to
generalize the study results to the research dealing with the other types of
cancer. The study sample included RCTs published only in English language
journals. W e cannot infer whether it is safe to generalize the study results to
RCTs published in other languages.

The article review was done by qualified reviewers who have different
backgrounds (Oncology, Epidemiology), which increased the generalizability of
the study results. The study sample is large and includes RCTs conducted in
many different institutions, groups, and countries. This variety also ensures good
generalizability of the study results. This study investigated RCTs that were
published in journals that had published more than four articles in the past 20
years. Therefore, the study results may not be applicable for RCTs published in
journals that publish cancer research infrequently.
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9.3

Future Research

There are several directions for future study. Given the observed kappa
agreement heterogeneity, further work in the assessment of the reliability of
individual CONSORT items is warranted. One potential method to conduct this
assessment is by using the checklist to score a sample of RCTs by multiple
reviewers. The fact that our data was extracted from published RCTs may be a
limitation to the strength of evidence obtained in our study. Performing a study
with prospective database might provide a higher level of evidence with regards
1

to addressing questions related to reporting quality.

Studies have shown that several scales were used to evaluate the
reporting quality of RCTs, but most of these scales have not been adequately
developed, nor have been adequately validated. Our study provides
complementary results to those from Moher et a l5Z, and highlights the need for a
more standardized method to assess the reporting of RCTs.
'x

Furthermore, It might be a good idea that the reporting guidelines
recommend that publishing journals require authors to use the standardized
scale to generate a score for their RCT as a mandatory step in the publication
process. This score could be included in the article index. Such score would give
the reader clear information on the article’s reporting quality before reading it.
This in turn might be a factor that draws the authors’ attention to the importance
of reporting quality and encourages them to strive for excellence in this regard.

Future scale development is likely to be most favourable if items common
to all trials are assessed, if the scale is straightforward to use, and if it is
developed with sufficient reliability. General consideration for the development of
a scale may include: definition of the quality assessed by the scale, definition of
the sample to be scored (published and/or unpublished RCTs in a specific field or
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in all medical fields), definition of research consumers that are going to use the
scale (same or different backgrounds), definition of application method (The use
of scoring sheet or training the reviewers), and open or blind-trial scoring.

9.4

Limitations

This study has a number of limitations and sources of bias. For example,
multiple testing can result in inclusion of “noise variables”, and different “best”
models may be obtained using other algorithms (e.g. forward stepwise). To
minimize the bias resulting from these two points, our analysis did not include
unnecessary tests; we only performed the necessary analyses required to
achieve credible results and to rule out confounding. W e also used SAS software
that properly accounts for the dummy variables in our model. More importantly, a
combination of epidemiological insight, the size of estimated regression
coefficients, the width of the confidence intervals, and the size of P-values rather
than relying exclusively on hypothesis tests drove the main effect modeling.

Another source of bias in this study was the fact that the two reviewers could
not be blinded to the journals’ names or authors. There might be a theoretical
incline to give high impact journals a higher score because of their reputation. If
this bias takes place in this study, it will similarly affect older and newer
publications resulting in no effect on the study’s conclusion regarding the
increase in reporting quality in recent publications.

Although we have included in our investigation all published RCTs, and
although there was no missing data, there is no clear way to evaluate how much
of these reports were “ improved” by the journal editors and peer-reviewers after
submission to the journal. If this “improvement” in fact exists, the variation from
journal to journal depending on their reviewers and editors remains unknown.
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In.the recent years, the Open Access Movement (the ability to publish in
online journals) has provided a new medium to publish, which increases the
chances of publishing RCTs.100 Therefore, the more recent an RCT is, the
greater its chances to be published. We have not included those RCTs that were
rejected for publication. The exclusion of these RCTs might have biased the pvalues downward (especially when testing the association of Year of Publication
with CONSORT Average Scores and Difference of Scores). Therefore, results
reported as statistically significant may in fact not be significant. The fact that
unpublished RCTs do not usually influence clinical practice justifies their
exclusion of the study sample.

Another limitation of our study was that we assessed publications only in
English and only involving Lung, Breast, Prostate and Colorectal cancer; the
study excluded other malignant diseases. Also, we did not have access to the
original study protocols nor did we interview the investigators who had
undertaken the studies for additional information.

Another limitation of our study was the fact that several trials included in
our sample did not specify age range for their inclusion/exclusion criteria. Thus,
our inclusion/exclusion criteria did not specify a range too.

W e did not examine our data to see whether some of the subjects in our
sample were published by the same author (research team). Reporting quality of
RCTs published by the same author are likely to be more similar than reporting
quality of RCTs published by different authors. Hence the assumption of
statistical independence, an assumption that is central for the validity of the
hypothesis testing, could be violated. The violation of this assumption produces
p-values that are too small. W e did not factor in this effect in our analysis
because of its small magnitude, since the number of RCTs published by the
same author in the sample is likely very small relative to the large sample size.

9.5

Conclusion

The findings of this study are summarized in the following points:

This study demonstrates a dose-response relationship in which more
recent publication year reflects an increase in reporting quality. There was an
increase of 3.1 CONSORT score points comparing an RCT published between
2002-2010 to an RCT published between 1992-1996, and an increase of 3.1
CONSORT score'points comparing an RCT published between 2002-2010 to an
RCT published between 1997-2001.

The higher the impact factor, the higher the

reporting quality was (higher CONSORT average score p<0.0001). RCTs
published in journals of a high impact factor have higher COSORT Average
score (1.46 point higher) compared to RCTs published in Journals of low Impact
Factor. The higher the author number, the higher the reporting quality
was (higher CONSORT Average score p<0.0001): There was an increase of 1
point in the CONSORT Score in published RCTs for an increase of about 7 in the
num ber of authors.
V
An overall two-way intraclass correlation coefficient of 0.71 (95%CI 0.610.78) for comparison of overall CONSORT score between the two reviewers.
Kappa agreement for each individual CONSORT checklist item ranged from
(0.02-0.92). Percent agreement for each individual CONSORT checklist item
ranged from (30.9 -97.8%). CONSORT Checklist items [Allocation mechanism
(Item # 9), Implementation (Item # 1 0 ) Flow for Patients (Item # 13a) Flow for
Loss to Follow up (Item # 13b) Generalizability (Item # 21) Interpretation (Item #
22)] were the least clear to interpret by the two reviewers. Table (6) presents
simple Kappa statistic and percent agreement for each of the CONSORT
Checklist items.
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- Recent year of publication was the only factor associated with an increase
in reliability of the CONSORT checklist items (decrease in the
CONSORT difference score which is considered predictor of variability
p<0.0001). There was a decrease in CONSORT Score difference comparing an
RCT published between 2002-2010 to an RCT published between 1992-1996
(p<0.0001). Although improvements in RCT reporting have been observed over
tim e in the cancer literature, the quality of reporting remains suboptimal (Mean
average CONSORT score was 16.6 [SD 3, max 25]).

Appendix I

SAS Programming

Kappas

options ls=120 ps=65;
%let root=S:\LRCP\CRU STATS\consort audit
libname save "&root\saveM;
libname library "&root\save";
ods rtf file=M&root\kappas.rtf";
data consort;
set save.consort;
proc freq;
table randl*rand2
desil*desi2
backl*back2
objel*obje2
desibl*desib2
partl*part2
settl*sett2
intel*inte2
priml*prim2
sampl*samp2
sequl*sequ2
genel*gene2
allol*allo2
impll*impl2
blinl*blin2
statl*stat2
flowl*flow2
flowbl*flowb2
recrl*recr2
basel*base2
numbl*numb2
primbl*primb2
harml*harm2
limil*limi2
genebl*geneb2
intebl*inteb2
regil*regi2
protl*prot2
fundl* fund2/agree;
* exact agree;
RUN;

Appendix II

SAS Programming - Descriptive Analysis and Main Effects Model

prop.' freq;
tables journal cancer year yeargroup intervention trial_site
multipleco primaryco coop journalonc consortl consort2 consortav
consortdiff IFgroupA;
run;
proc univariate;
var authorno- patientno IF2009 consortl consort2 consortav
consortdiff;
run;
proc glm;
class Cancer Intervention Trial_Site Coop Journalonc Yeargroup;
model consortav = Cancer Intervention Trial_Site Coop Journalonc
Yeargroup authorno patientno IFgroupA / solution;
run;
proc glm;
class Cancer Intervention Trial_Site Coop Journalonc Yeargroup;
model consortdiff = Cancer Intervention Trial_Site Coop Journalonc
Yeargroup authorno patientno IFgroupA / solution;
run;

Cancer_lung=0; Cancer_breast=0;Cancer_jprostate=0;
if Cancer=l then Cancer_lung=l;
if Cancer=2 then Cancer_breast=l;
if Cancer=3 then Cancer_prostate=l;
Intervention_radiation=0;Intervention_chemo=0;Intervention_surgical

0;

'

if Interventions then Intervention_radiation=l;
x
if Intervention=2 then Intervention_chemo=l;
if Intervention=3 then Intervention_surgical=l;
y
Trial_Site=0;
if Trial_Site=l then Trial_site=l;
Coop=0;
if coop=l then coop=l;
Journalonc=0;
if Journalonc=l then Journalonc=l;
Yeargroupq=(Yeargroup le 19 9 6 ) + 2 * (Yeargroup ge 1997 and lwt le
2001) + 3 * (Yeargroup ge 2002);
Yeargroupl=0;Yeargroup2=0;
if (Yeargroupq=l) then Yeargroupl=l;
if (Yeargroupq=2) then Yeargroup2=l;

proc reg;
model consortav=
{Cancer__lung Cancer_breast Cancer_j?rostate}
{Intervention_radiation Intervention^chemo Intervention_surgical}
{Yeargroupl Yeargroup2}

Trial_Site Coop Journalonc
authorno patientno IFgroupA /
selection=backward
/* Creating Revised Predictors and Dummy Variables */
ftvb=0;
if ftv ge 1 then ftvb=l;
race_white=0;race_other=0;
if race=l then race_white=l;
if race=3 then race_other=l;
lwtq=(lwt le 109) + 2 * (lwt ge 110 and lwt le 120)
+ 3 * (lwt ge 121 and lwt le 138)
+ 4 * (lwt ge 139);
lwt2=0;lwt3=0;lwt4=0;
if (lwtq=2) then lwt2=l;
if (lwtq=3) then lwt3=l;
if (lwtq=4) then lwt4=l;
ptlb=0;
if ptl ge 1 then ptlb=l;

/* Main Effects Model - FTV binary */
proc reg;
model bwt=smoke {age age2} ftvb
{race__white race_other}
{lwt2 lwt3 lwt4}
ht ptlb ui /
selection=backward
groupnames="Mother7s smoking status"
"Mother's age"
"Num. doc visits"
"Mother's race"
"Mother's pre-pregnancy weight"
"Mother's history of hypertension"
"Number of premature labors"
"Uterine irritability"
include=3;

Appendix III

SAS Programming - Backward Elimination

proc reg;
model consortav = Cancer Intervention Trial_Site Coop Journalonc
Yeargroup authorno patientno IFgroupA /
selection=backward;
run ;

proc reg;
model consortdiff = Cancer Intervention Trial_Site Coop Journalonc
Yeargroup authorno patientno IFgroupA /
selection=backward;
run;
•
■

Appendix XII

Permission Letters
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Citation: Material appearing in this publication may be reproduced or copied
without permission; however, the following citation must be used to indicate the
source:
Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian
Cancer
Statistics 2011. Toronto, ON: Canadian Cancer Society; 2011.
May 2011
ISSN 0835-2976

From: Canadian Cancer Society <hamiltoncis@cis.cancer.ca>
To: iarra2@uwo.ca
Sent: Mon, June 27, 2011 3:08:25 PM
"
Subject: Permission to use figures as reference (Date 06/27/2011 User 239)

Q

Dear Ian,
Thank you for contacting the Canadian Cancer Society's Cancer Information
Service. Your email has been forwarded to us by our National office.
In the Canadian Cancer Statistics 2010 booklet, if you go to the first page titled
Steering Committee Members, towards the bottom of the page you will see a
section titled Citation. There you will read how the exact wording should be when
you cite information from the statistics book.
If you have any questions or comments, don't hesitate to contact us again, and
good luck with your thesis.
Sincerely,
Lynn, Cancer Information Specialist

Citing the CONSORT Statement from the website (for authors)
W hen referring to the CONSORT Statement, we recommend using journal article
citations rather than referring to the CONSORT Statement website. If you are not
already using a journal article citation, please cite one of the following original
publications of CONSORT 2010:.
CONSORT 2010 Statement
•

.

•

•

•

Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT
2010 Statement: updated guidelines for reporting parallel group
randomised trials. Ann Int Med 2010:152. Epub 24 March.
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT
2010 Statement: updated guidelines for reporting parallel group
randomised trials. BMC Medicine 2010, 8:18. (24 March 2010)
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT
2010 Statement: updated guidelines for reporting parallel group
randomised trials. BMJ 2010;340:c332.
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT
2010 Statement: updated guidelines for reporting parallel group
randomised trials. J Clin Epi 2010;
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT

2010

•

.

•

statement: updated guidelines for reporting parallel group randomized
trials. Obstet Gynecol 2010; 115(5):[pages TBD].
Schulz KF, Altman DG, Moher D; for the CONSORT Groups CONSORT
2010 Statement: updated guidelines for reporting parallel group
randomized trials. Open Med 2010:4(11:60-68.
Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010
Statement: Updated Guidelines for Reporting Parallel Group Randomised
Trials. PLoS Med 2010:7(3): e1000251. .
doi:10.1371/iournal.pmed. 1000251
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT
2010 Statement: updated guidelines for reporting parallel group
randomised trials. Trials 2010, 11:32. (24 March 2010)

CONSORT 2010 Explanation and Elaboration
Since the CONSORT Statement should be read in conjunction with the
CONSORT Explanation and Elaboration document, you should also be using and
citing:
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\

• . Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux
PJ, Elbourne D, Egger M, Altman DG, for the CONSORT Group.
CONSORT 2010 Explanation and Elaboration: updated guidelines for
reporting parallel group randomised trial. BMJ 2010;340:c869.
• Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux
PJ, Elbourne D, Egger M, Altman DG, for the CONSORT Group.
CONSORT 2010 Explanation and Elaboration: updated guidelines for
reporting parallel group randomised trial. J Clin Epi 2010;

Using the CONSORT Statement
The CONSORT Statement and the CONSORT Explanation and Elaboration
Document are distributed under the terms of the Creative Commons Attribution
License, which permits use, distribution, and reproduction in any medium,
provided the original author and source are credited.
However, because the guidelines represent a consensus agreed through
successive drafts by the CONSORT Group, they should not be edited or modified
in any way, although it is acceptable to publish portions (e.g., the summary).
Page last edited: 16 May 2011
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